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Abstract
Insulin is a mitogen for many cells and commonly signals through the classical, mitogenic Raf-
MEK-ERK or metabolic PB-kinase pathways. Insulin deficiency or type I diabetes causes
severe osteopenia. Obese patients with type II diabetes or insulin resistance, a disease associated
with defective insulin signaling pathways and high levels of circulating insulin, have increased
or normal bone mineral density. The question of whether hyperinsul inemia preserves bone mass
is frequently raised. However, there is still a lot of controversy on the role of insulin as an
osteoanabolic agent and this question still remains unanswered. A critical role for insulin
signaling in bone building osteoblasts has recently been demonstrated with IRS-l knock-out
mice. These mice developed low-turnover osteopenia due to impaired proliferation and
differentiation, stressing the importance of osteoblastic IRS-l for maintaining normal bone
formation.
In the present study it was found that insulin does function in vitro as an osteoblast mitogen.
This was illustrated in three relatively immature osteoblast (MBA-15.4, -15.6 mouse and MG-
63 human) cell lines, which responded to insulin with significant increases in proliferation. In
the MBA -15.4 preosteoblasts insulin stimulation of proliferation was comparable to the well-
described mitogen, TPA. The UMR-I06 cell line expresses markers of differentiated
osteoblasts, and was much less responsive to insulin treatment. The difference in proliferative
potential may be due to differences between spontaneously transformed cell lines, or the stage
of cell differentiation.
UOI26, a MEKI/2 inhibitor and wortmannin, a PB-kinase inhibitor, were used to investigate the
pathway used by insulin to signal and activate ERK and osteoblast proliferation. In MBA-15.4
mouse preosteoblasts, GF-containing FCS was completely dependent on MEK for DNA
synthesis. In contrast, in both MBA-15.4 and more mature MBA-15.6 osteoblasts, insulin-
induced proliferation was resistant to the inhibitors alone or in combination. Higher MEK-
inhibitor concentrations had no effect, and proliferation was also increased by the inhibitors in
several experiments. This indicated that the classical, insulin mitogenic pathway was not
involved in MBA-15.4 proliferation. Wortmannin had no effect on either insulin- or 20% FCS-
stimulated proliferation, but inhibited activation of Akt/PKB, the metabolic downstream target
of PI3-kinase. Insul in signal ing to ERK was both MEK-and PI3-kinase- dependent, but this had
no effect on proliferation. In contrast, FCS-stimulated ERK activation and proliferation was
almost completely dependent on MEK-ERK activation.
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Proliferative signaling in the MG-63 human osteoblastic cell line in response to insulin was
partially dependent on MEK and partially dependent on PB-kinase. In contrast, signaling in
response to the phorbol ester, TPA, was partially dependent on PI3K but totally dependent on
MEK-ERK. This indicates that the signal converges on ERK, suggesting the involvement of a
PB-kinase upstream of a dominant MEK-ERK pathway. The differences found here between
mouse and human insulin mitogenic signaling pathways indicate that there may be species
differences between osteoblast signaling pathways, with mouse cells being independent and
human cells being dependent on MEK for DNA synthesis in response to insulin.
The effects of glucocorticoids on insulin mitogenic signaling in osteoblasts were also
investigated, because chronic long-term steroid use results in excessive bone loss. The PTP
inhibitor, sodium orthovanadate, reversed GC-impaired TPA- and FCS- induced proliferation in
MBA-1SA and MG-63 preosteoblasts. PTPs, such as SHP-l and PTP-IB, dephosphorylate and
inactivate phosphorylated kinases. Both SHP-l and PTPlB associated with kinases in the
mitogenic signaling cascade of MBA-lS.4 preosteoblasts growing rapidly in 10% FCS. Further,
SHP-I co-irnmunoprecipitated with active, tyrosine phosphorylated ERK, which may indicate
that it can dephosphorylate and inactivate ERK. However, since the MEK-ERK or PB-kinase
pathways are not important in insulin-induced proliferation in mouse osteoblasts, the PTPs are
unlikely to be role players in the negative regulation of this signaling pathway. This was
confirmed by the finding that vanadate was unable to reverse GC-induced decreases in insulin-
stimulated DNA synthesis. This suggests that vanadate-sensitive PTPs may not be important in
the negative regulation of insulin-induced mouse osteoblast proliferation, and provides further
evidence of a novel insulin mitogenic pathway in the MBA-lSA but not MG-63 osteoblastic
cell line.
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Abstrak
Insulien is 'n mitogeen vir baie selle en gelei na binding aan die insulien reseptor, intrasellulêre
seine via die klassieke, mitogeniese Raf-MEK-ERK of die metaboliese PB-kinase
seintransduksie pad. 'n Insulien gebrek of tipe I diabetes veroorsaak osteopenie. Vetsugtige
pasiënte met insulien weestandigheid of tipe II diabetes, 'n siekte wat geassosieer word met
foutiewe insulien seintransduksie en hoë vlakke van sirkuierende insulien, het verhoogde of
normale been mineraal digtheid (BMD). Die vraag of hiper insulin ernie 'n verlies aan beenmassa
teëwerk word dikwels gevra. Teenstrydigheid oor die rol van insulien as 'n osteo-anaboliese stof
bestaan egter steeds en hierdie vraag bly dus onbeantwoord. Dat insulien seintransduksie wel 'n
kritiese rol speel in beenvormende osteoblaste is onlangs bevestig in studies met muise waarvan
die geen vir IRS-l uitgeslaan is. Hierdie muise ontwikkel 'n lae omset osteopenie weens
verswakte proliferasie en differensiasie.
fn hierdie studie is gevind dat insulien wel in vitro as 'n osteoblast mitogeen kan funksioneer.
Dit is in drie relatief onvolwasse (MBA-15.4, -15.6 muis en MG-63 mens) sellyne geillistreer,
deur betekenisvolle verhogings in insulien-geaktiveerde proliferasie. In MBA-15.4 pre-
osteoblaste is die persentasie verhoging in insulien-gestimuleerde proliferasie vergelykbaar met
dié van die bekende mitogeniese forbolester, TPA. Die UMR-I06 sellyn het kenmerke van
gedifferensieerde osteoblaste, en was baie minder responsief op insulien behandeling. Die
verskil in die proliferasie vermoë van die verskillende sellyne kan die gevolg wees van verskille
wat bestaan tussen spontaan getransformeerde sellyne of die stadium van sel differensiasie.
'n MEK 1/2 inhibitor, UO126 en 'n PB-kinase inhibitor, wortmannin, is gebruik om die insulien
seintransduksie pad noodsaaklik vir die aktivering van ERK en osteoblast proliferasie te bepaal.
In MBA-1S.4 muis pre-osteoblaste, was fetale kalf SenlTI1(FKS)-geinduseerde DNA sintese
totaal afhanklik van MEK. Beide die MBA-15.4 en die meer volwasse MBA-15.6 muis
osteoblaste was weerstandig teen die inhibitors op hulle eie, of in kombinasie. Verhoogde
MEK-inhibitor konsentrasies het geen verdere effek gehad nie en in verskeie eksperimente is 'n
verhoging in preliferasie selfs waargeneem met MEK-inhibisie. Hierdie resultate dui aan dat die
klassieke insulien mitogeniese pad nie betrokke is in MBA-I5.4 gestimuleerde selproliferasie
nie. Wortmannin het geen effek gehad op insulien- of20% FKS-gestimuleerde DNA sintese nie,
maar het wel die aktivering van PB-kinase se metaboliese teiken, AktJPKB geinhibeer. Insulien
seintransduksie aktiveer dus ERK deur beide MEK en PB-kinase, maar het geen effek op
proliferasie gehad nie. FKS-gestimuleerde ERK aktivering en proliferasie was totaal afhanlik
van MEK-ERK aktivering.
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Insulien-geaktiveerde DNA sintese in die mens MG-63 osteoblaste was gedeeltelik afhanklik
van beide MEK en PB-kinase. Alhoewel IPA ook PB-kinase kon aktiveer, was dit totaal
afhanklik van MEK vir DNA sintese. Dit dui aan dat daar 'n PB-kinase stroom-op van 'n
dominante MEK-ERK seintransduksie pad voorkom. Die verskille wat ons dus waargeneem het
in insulien mitogeniese seintransduksie tussen muis en mens, kan aandui dat insulien-
gestimuleerde seintranduksie paaie kan verskil van spesie tot spesie. Dit is bevestig met die
muisselle wat onafhanklik is en mens selle wat afhanklik is van MEK aktivering vir insulien-
geaktiveerde DNA sintese.
Kroniese, langtermyn steroied behandeling kan beenverlies veroorsaak en die effek van
glukokortikoide (GK) op die insulien mitogeniese pad in osteoblaste is dus ook ondersoek.
Natrium-ortovanadaat, 'n proteien tirosien fosfatase (PIP) inhibitor het GK-verlaagde
proliferasie in repons tot beide IPA- en FKS behandeling herstel in MBA-lSA en MG-63
preosteoblaste. PIPs soos SHP-l en PIP-l B funksioneer deur gefosforileerde kinases te
defosforileer en dus te inaktiveer. Beide SHP-l and PIP-lB kon assosieer met kinases in die
mitogeniese insulien seintransduksie pad van vinnig groeiende MBA-IS A preosteoblaste in
10% FKS. Verder het SHP-I ook geko-immunopresipiteer met aktiewe, tirosien-gefosforileerde
ERK, wat aandui dat SHP-I met ERK assosieer om dit te defosforileer en inaktiveer. Die MEK-
ERK of PB-kinase paaie is nie belangrik vir insulien-geaktiveerde seintransduksie in muis
osteoblaste nie. Dit is dus onwaarskynlik dat die PIPs 'n rol sal speel in die negatiewe
regulering van hierdie seintransduksie paaie. Die ontdekking dat vanadaat nie glukokortikoied-
verlaagde insulien-geaktiveerde DNA sintese kan herstel nie, toon dat vanadaat-sensitiewe PIPs
nie 'n rol speel in insulien-geaktiveerde proliferasie in muisselle nie. Hierdie bevinding het
verder bevestig dat 'n nuwe insulien mitogeniese pad in die MBA-ISA, maar nie die MG-63
selle moontlik bestaan.
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CHAPTERt
INTRODUCTION
A. BONE
1. BOlle regeneration
The skeleton is a single organ comprised of two tissues, cartilage and bone (For reviews, see
Manolagas, 2000; Eriebacher et al, 1995; Watkins et al, 2001). During development and growth the
skeleton is continuously regenerated. The bones of a growing child change in shape and size by a
process called modeling. During modeling, 100% of the bone surfaces are active, allowing continuous
changes in skeletal mass and morphology. Once the skeleton has reached maturity, it undergoes
remodeling, a periodic replacement of old bone with new at the same location. Only 20% of the bone
surfaces are being remodeled at any given time, resulting in the complete regeneration of the adult
skeleton every 10 years (Parfitt, 1994). Bone is usually replaced when it is too old or damaged to carry
out its function. In bones that are load bearing, remodeling most likely serves to repair fatigue damage
and to prevent excessive aging.
1.1 Remodeling by the basic multicellular u/lit (EMU)
Two cell types occur in bone, osteoblasts, the bone forming cells and osteoclasts which resorb bone
(See Fig.!). In 1965, Hattner et al., observed that new bone is formed in areas which had recently
undergone resorption. This remodeling of bone is tightly controlled and is carried out by temporary
structures known as basic multicellular units or BMUs (Parfitt, 1994). Each BMU is a discrete packet
consisting of osteoclasts in the front and osteoblasts in the rear. Each functions within a defined
remodeling cycle separately from other BMUs. The cycle begins when a non-remodeling bone surface
becomes activated. The osteoclasts move in, attach to bone in need of replacement, and remove it by
acidification and proteolytic digestion. As the BMU advances, osteoclasts leave the resorption site and
osteoblasts move in to cover this area with new bone by secreting osteoid which is eventually
mineralized into new bone. There are two types of bone, cortical (compact) or cancellous (trabecular)
bone. In dense cortical bone the BMU makes a tunnel through the tissue, while in cancellous bone they
form a trench by moving across the trabecular surface (Manolagas and Weinstein, 1999). The lifespan
of the BMU is 6 months and millions of areas of bone are remodeled at any moment in a healthy
human adult. Although the amount of bone resorbed and formed during each cycle of remodeling is
tightly balanced, deregulation negatively affects bone mass, causing many metabolic bone diseases.
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22. Origin of osteoblasts
Osteoblasts originate from common multipotent mesenchymal stem cells in the bone marrow, which
can differentiate into other cell lineages, such as chondrocytes, muscle cells, adipocyes and bone
marrow stromal cells (Grigoriadis et ai, 1988; Nuttall et al, 1998). Preosteoblasts are found one or two
cell layers away from mature osteoblasts (Watkins et aI, 2001). Once in the correct position on the
bone surface, osteoblasts deposit bone matrix or osteoid. This marks their differentiation and they can
then be defined as mature osteoblasts. Osteoid is predominantly composed of type I collagen but also
contains other non-collagenous proteins such as osteopontin, osteonectin and osteocalcin. The
developing matrix or osteoid is eventually mineralized with calcium and phosphate. Matrix synthesis
determines bone volume, while mineralization increases bone density.
During the differentiation process from mesenchymal progenitors, various hormones and cytokines
regulate osteoblast differentiation. These regulatory molecules are temporarily expressed and induce
nonosteogenic cells to differentiate into mature osteoblasts. Among these, bone morphogenetic
proteins (BMPs) not only stimulate normal osteoprogenitors to differentiate into mature osteoblasts,
but can also experimentally induce nonosteogenic cells to differentiate into osteoblast lineage cells
(Yamaguchi et al, 2000). BMPs stimulate the transcription of the gene encoding core binding factor
al (Cbfa-L), an osteoblast transcription factor. Cbfa-I is initially expressed in cells of the
mesenchymal condensation (Ducy et aI, 1997). lts expression becomes restricted to osteoblasts during
development and after birth (Karsenty, 1999). In tum, Cbfa-l regulates the expression of many
osteoblast specific genes and is required to produce a bone extracellular matrix (Wagner and Karsenty,
2001). Besides Cbfa-I, various other transcription factors, such as members of the AP-I (activator
protein-I) complex, are also involved in osteoblast growth and differentiation (Jochum et aI, 2001).
3. Origill of osteoclasts
The precursors of the osteoclasts are hematopoietic cells of the monocyte/macrophage lineage. The
recent discovery of three proteins has greatly clarified the role that osteoblasts play in
osteoclastogenesis (Fig.I; See review by Suda et aI, 1999). Firstly, receptor activator of NF-KB
(RANK)-ligand, is expressed in committed preosteoblastic cells and T-lymphocytes (Kong et aI,
1999). It is initially made as a membrane-bound molecule and subsequently released from the
membrane through proteolytic cleavage (Lum et al, 1999). Both soluble and membrane bound RANK-
ligand bind with high affinity to RANK (HSl! et al, 1999).
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Figure I.Molecular control of bone remodeling and bone disease. RANK-ligand
expressed in preosteoblastic cells and T-lymphocytes binds to RANK on osteoclast
progenitors. RANK! RANK-ligand interaction is required for osteoclastogenesis.
OPG acts as a decoy receptor and blocks the RANK! RANK-ligand interaction.
(Modified from Kong and Penninger, 2000)
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4RANK is an integral membrane protein that is expressed in hematopoietic osteoclast progenitors. The
RANK/RANK-ligand interaction is essential and together with monocyte macrophage colony
stimulating factor (M-CSF), sufficient for osteoclastogenesis (Manolagas, 2000). Osteoclast
development is thus dependent on cell-to-cell contact between RANK-ligand expressed on osteoblasts
and its receptor, RANK, on osteoclast precursors (Burgess et aI, 1999). The third of the three proteins
is a soluble receptor called osteoprotegerin (OPG) (Simonet et al, 1997). OPG blocks the
RANK/RANK-ligand interaction by acting as a decoy or a neutralising receptor (Yasuda et aI, 1998).
The ratio of RANK-ligand/ OPG interaction is an important regulatory mechanism in osteoclast
maturation and osteoclasts activation in vitro and in vivo (Lacey et aI, 1998). Both the murine and
human RANK-ligand genes contain two functional Cbfa-I sites, and mutation of these sites abolish
the transcriptional activity of the RANK-ligand gene promoter (Manolagas, 2000). Since BMP-2 and-
4 stimulate Cbfa-l expression, it has been postulated that a BMP- Cbfa-l- RANK-ligand gene
expression cascade exists in ce1ls of the bone marrow/ osteoblastic lineage (Abe et al, 2000). This
cascade may control the rate of bone regeneration and maintain the continuous supply of osteoblasts
and osteoclasts.
4. Death of osteoblasts and osteoclasts
The average life span of the BMU is 6 months (Manolagas and Weinstein, 1999). Human osteoclasts
and osteoblasts have an average lifespan of about 2 weeks and 3 months, respectively. After
osteoclasts have eroded to a particular distance, they die and are quickly removed by phagocytes. Most
of the osteoblasts (65%) that assembled originally at the remodeling site also die (Jilka et al, 1998).
The remaining osteoblasts are converted to lining cells that cover quiescent bone surfaces or they
become embedded in the mineralized matrix as osteocytes (Rodan, 1992). Both osteoblasts and
osteoclasts die by apoptosis. However, the selective regulation and mechanistic pathways that initiate
apoptosis during the bone turnover processes are still not understood in any detail (Hock et aI, 2001).
5. Bone disease
To maintain total bone mass, bone formation (osteoblast activity) and resorption (osteoclast activity)
must be balanced. An imbalance can result in the formation of either too much bone (osteopetrosis) or
too little bone (osteoporosis). Defects in osteoclast differentiation or function are associated with
multiple genetically inherited or acquired diseases, all characterized by an arrest of bone resorption
(Lazner et a l, 1999). Clinical disorders in which bone resorption is increased include Paget's disease,
postmenopausal osteoporosis and bone changes secondary to cancer (Kong and Penninger, 2000).
Bone loss occurs in all individuals (males and females) after mid-life and is part of the natural aging
process (Mundy, 2000). However, osteoporosis is more common in elderly women than in men
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5(Rizzoli et al, 2001). Possible reasons for the difference is that women have less bone mass at their
peak (young adult), which in females accelerates at menopause because of estrogen deficiency (Riggs
et ai, 1998). Men do not experience a period of accelerated bone loss (menopause) and lose bone more
slowly (Bilezikian et al, 1999). Only in acute hypogonadism is bone loss in men rapid, similar to
menopausal bone loss in women (Mauras et aI, 1999). Postmenopausal osteoporosis also referred to as
type Iosteoporosis is the most common disorder of bone. Type II or senile osteoporosis occurs mostly
in individuals over 70 years of age (Cohen and Roe, 2000). The disease occurs when too little of both
bone formation and resorption causes a gradual shrinking of bone mass which is slow and age related
(Wick et ai, 2000). Reduced bone resorption or osteopetrotic diseases are relative rare in humans e.g.
pycnodysostosis due to Cathepsin K deficiency (Saftig et ai, 1998). The bone marrow is progressively
replaced by the bone extracel1ular matrix that is continuously deposited by the osteoblasts. Since there
is an increase in matrix formation, osteopetrotic bones are characterized by a much denser appearance
than normal. Although several animal models are available to study osteopetrosis, there are limitations
to using these models when looking for possible therapies (McLean and Olsen, 2001). The human
equivalents of the various animal mutations have not been identified (Lazner et aI, 1999). In addition
to Type I and Type II osteoporosis, prolonged and high dose treatment with glucocorticoids (GCs) is
the third leading cause of osteoporosis.
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6B. GLUCOCORTICOID-INDUCED OSTEOPOROSIS
1. Introduction
The introduction of GC drugs into clinical practice has provided treatment for a diverse group of
conditions including asthma, rheumatoid arthritis and several other inflammatory diseases. However,
reports of fractures in patients receiving steroid treatment soon appeared, and GC-induced
osteoporosis has remained a clinical problem ever since (Reid, 1997). The loss of bone is biphasic,
with a rapid initial phase of about 12% during the first 6-12 months, followed by a slower phase of
about 2-5% each year. Cortical and cancellous bone are lost, but steroids affect the axial skeleton more
severely, manifested by spontaneous fractures of the vertebrae or ribs (Manolagas, 2000).
Osteonecrosis, can also occur, which causes collapse of the femoral head in about 25% of patients
(Pritchett, 200 I).
2. Molecular mechanisms of glucocorticoid action
Effects of lipophilic GCs (cortisol in man, guinea pig and rabbit; corticosterone in rodents) are
mediated by an intracellular receptor, the glucocorticoid receptor (GR) (Hollenberg et al, 1985). GR
belongs to the nuclear hormone receptor superfamily (Beato et al, 1995). After passing the plasma
membrane, GCs bind to GR. Steroid hormone receptors together with heat shock proteins are trapped
in an inactive cytosolic complex, in the absence of a ligand. Upon ligand binding, associated heat
shock proteins are released and the ligand-bound receptor translocates into the nucleus (Reichardt and
Schiltz, 1998). Once in the nucleus, the GC-GR complex can utilize several different mechanisms in
order to influence gene expression (Reviewed by Aranda and Pascual, 2001). Upon binding of the
activated GR as a homodimer to the glucocorticoid-response elements (GREs), or negative GREs
(nGREs) it can induce or repress the transcription of target genes (Sakai et al, 1988). Some genes
lacking GREs or nGREs in their promoters can still be affected by GCs. By "transcriptional cross-
talk" of GR with other transcription factors, the gene expression pattern within cells can be influenced
by GR wi thout its binding to DNA (Gëttlicher et aI, 1998). Well known examples include the GR and
AP-I transcription factor interacting on target gene promoters which contain binding sites for only one
class of factors, either AP-lor steroid hormone receptors (Wei and Vedeckis, 1997). Negative
interference of both factors with each other's activity has been observed. For example when AP-I is
bound to its cognate DNA-recognition site, the GR can modulate AP-I activity through protein-protein
interaction. Depending on the composition of the AP-I complexes they can either co-operate or
antagonize transcription by the GR. The GR represses AP-I activity when it is composed of c-Fos and
c-Jun (Yang-Yen et al, 1990). However, synergism is possible under cell-specific conditions and
when AP-I is a homodimer of c-Jun (Diamond et al, 1990).
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GCs have profound effects on bone metabolism, acting at many sites (Fig. II). GCs increase bone
resorption and decrease bone formation, leading to a decrease in bone mass and a higher risk of
fractures (Canalis, 1996; Ziegler and Kasperk, 1998). In vivo, a cause of excessive bone resorption is
enhanced stimulation of parathyroid hormone (PTH) secretion or activity (McSheehy and Chambers,
1986). Although GCs can directly stimulate PTH secretion, PTH secretion is mainly stimulated by the
negative serum calcium levels caused by a decrease in intestinal calcium absorption and increasing
urinary calcium secretion (Au, 1976; Suzuki et aI, 1983). GCs increase osteoblast PTH receptor
expression, enhancing their responsiveness to PTH. Osteoblast recruitment and differentiation is
inhibited by high-dose GCs. This is associated with reduced collagen type I production and osteocaIcin
synthesis, which are markers of osteoblastic function (Wong et aI, 1990; Delany et aI, 1995).
Collagenase 3 production may be increased, which degrades collagen type I, a structural protein of the
bone matrix (Delany et al, 1995).
GCs can indirectly affect bone growth by opposing the effects of osteoblast growth factors such as
insulin-like growth factor (IGF)-I, IGF-2 and transforming growth tactor-B (TGF-I3). IGF-l, -2 and -3
are secreted by mature osteoblasts and stimulate osteoblast proliferation and differentation through
specific membrane receptors (Thomas et aI, 1999). The activity of IGF is regulated by six IGF-binding
proteins (IGFBP), which are all expressed by osteoblasts (Rechler and Clemmons, 1998). IGFBP-5
enhances the effects of IGF-l and IGFBP-6 inhibits IGF-2. GCs decrease IGFBP-5 synthesis and
increases IGFBP-6 production, thus decreasing the amounts of IGF-l and IGF-2 available to bone
cells (Canalis, 1998). GCs inhibit TGF-I3·activity and suppress binding to its receptor TGF-13type I on
osteoblasts. In addition, binding sequences for the osteoblast transcription factor Cbfa-l , occur in the
TGF-13 type I receptor promoter (Ji et aI, 1998). This may explain the observation that GCs suppress
Cbfa-l causing a decrease in TGF-13 type I receptor expression and activity (Chang et al, 1998). The
decrease in osteoblast numbers and the increase in osteoclast activity produce a marked decrease in
bone formation. However the diverse and complex effects of GCs on bone metabolism are still
incompletely understood, mainly due to differences in experimental outcomes in different systems and
culture conditions (Ishida and Heersche, 1998).
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Figure II. Sites and mechanism ofGC effects on bone metabolism in humans. (Modified from Manelli
and Giustina, 2000).
4. Glucocorticoids and bone formation
Impairment of osteoblast numbers is one of the main contributors to GC-induced bone loss. The
demonstration of GR in osteoblasts, suggested a direct effect of GCs on osteoblast function (Feldman
et aI, 1975; Chen et aI, 1977). In vitro. the effects of GCs are dose-dependent. Low concentrations
stimulate osteoblast differentiation and increase matrix synthesis in mature osteoblasts (Shalhoub et aI,
1992). However, high-dose GCs cause inhibition of type I collagen and alkaline phosphatase gene
expression and decreased action of growth factors (GF), in particular IGF-I (Canalis, 1996). In vivo,
prolonged treatment with even physiological GC doses causes osteoporosis (Ebeling et aI, 1998). The
constant long-term GC administration results in supraphysiological GC levels and a loss of the normal
circadian pattern of cortisol secretion. This is comparable to the inhibitory effects seen in vitro when
GC dose is increased beyond optimal concentrations (Ishida and Heersche, 1998).
Hulley et aI., (1998) have shown that GC treatment of a preosteoblastic cell line induces decreased
response to GFs of the mitogenic Raf-MEK-ERK kinase cascade, impairing osteoblast proliferation
(Table 1). Further, since the osteoblast transcription factor Cbfa-I is downstream of extracellular
signal regulated kinase (ERK), decreased ERK activity would negatively affect Cbfa- I transcription
and bone growth (Xiao et al, 2000). The protein tyrosine phosphatase (PTP) inhibitor, sodium
orthovanadate, reversed the effects of Dexamethasone (Dex), suggesting the involvement of PTPs,
possibly by GC-induced up-regulation (Hulley et aI, 1998). Hulley et aI., (2001) confirmed this result
in a GC-induced osteoporotic rat model. Daily vanadium supplementation increased osteoblastic bone
formation, thus improving bone mineral density (BMD) and bone strength (Hulley et aI, 2001). These
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9studies indicated that high dose GCs inhibit the mitogenic cascade and that the PTP inhibitor vanadate
is effective in preventing this. Vanadate would act effectively either if GCs up-regulate PTPs causing
excessive or rapid dephosphorylation of kinases, or if specific tyrosine phosphorylated substrates are
down-regulated by GC, resulting in a net imbalance of kinase vs PTP activity. Clinically, vanadate has
been shown to improve insulin sensitivity and decrease glucose levels in both diabetic animals
(Meyerovitch et al, 1987; Briehard et al, 1988) and humans (Cohen et al, 1995; Goldfine et al, 1995).
Possible targets of vanadate action are the PTPs, PTP-lB and SHP-1. PTP-IB is a negative regulator
of insulin signaling (Goldstein et aI, 2000), while SHP-l has been reported to dephosphorylate the
insulin receptor (Bousquet et aI, 1998) and to be up-regulated by GCs (Cambillau et aI, 1995). By
preventing dephosphorylation of specific tyrosine phosphorylation sites (i.e. insulin receptor and
insulin receptor substrate-I), vanadate effectively turns off a negative switch, providing a prolonged
active state of important insulin signaling events.
Recent findings indicate that GCs also promote apoptosis of the bone forming cells. Mice treated with
GCs show a three-fold increase in osteoblast apoptosis, while 28% of the osteocytes died by apoptosis
(Weinstein et aI, 1998). Preliminary studies indicate that overexpression of the Bc1-2 gene reduced
GC-induced apoptosis (Bellido et al, 1998). A possible mechanism is that GCs, by lowering the levels
of anti-a pop to tic protein Bcl-2 and raising levels of Bax, an apoptosis-inducer, apoptosis in osteoblasts
is promoted (Mocetti et aI, 2001). Since GFs such as insulin have pronounced anti-apoptotic effects,
decreased response or "GF resistance" caused by GCs would also favour apoptosis. An additional loss
of osteoblasts may be explained by increased fat formation in the bone marrow of mice and humans
with GC excess as a result of increased expression of peroxisome proliferator-activated receptor
(PPAR)-y2, a transcription factor that induces terminal adipocyte differentiation while suppressing
osteoblast differentiation (Lecka-Czernik et al, 1999).
Table 1. Cellular changes and possible agents in glucocorticoid-induced osteoporosis
Cellular changes Possible agents
.J.osteoblastogenesis decreased Cbfa-l and TGF-p type I receptor;
decreased BMP2 and IGF-I action, #GF
resistance
t .J.osteoclastogenesis*
i bone marrow adipocity
increased PPARy2 expression
.J.lifespan of osteoblasts
.J.lifespan of osteocytes
decreased Bel-21 BAX ratio, #GF resistance
decreased Bcl-21 BA.-Xratio, #GF resistance
*Osteoclast numbers may increase transiently at the early stages of steroid therapy, but decrease subsequently;
osteoclast activity may increase due to increased PTH (Table modified from Manolagas SC and Weinstein RS,
#1999; Hulley et al, 1998)
Stellenbosch University http://scholar.sun.ac.za
10
5. Treatment (Possible bone builders)
Many more drug therapies are available to reduce bone resorption, than to stimulate bone formation.
For example, hormone replacement therapy, bisphosphonates and fluoride are conunonly prescribed
for treatment of Type I osteoporosis (López, 2000). For most anabolic agents the side effects outweigh
the benefits of modest increases in bone mineral density. For example, fluoride treatment produces
increases in trabecular bone volume and lumbar spine BMD (Lems et al, 1997; Farley et aI, 1983).
However, at high doses it interferes with normal mineralization, increasing bone fragility (Hedlund
and Gallagher, 1989). Anabolic steroids and testosterone treatment have also been shown to increase
bone mass (Libanati and Baylink, 1991). However, side effects include prostate cancer and severe
cardiac and hepatic diseases (Avila et aI, 2001; Farrell et aI, 1975).
It is clear that the ideal therapy for the treatment of GC-induced bone loss would be the use of agents
that enhance bone formation. Other possible bone anabolic agents include growth hormone (GH) and
PTH. GH secretion declines with age both in humans and in rats. In old female rats GH injections and
mild exercise in combination modulate and increase further the formation and strength of cortical bone
(Oxlund et aI, 1998). In a young (2 months old) rat model, GH increased growth in GC-injected
animals, but the effect was however, dose-dependently decreased by GC-administration (0rtoft et aI,
1999). When female rats (31'2 months old) were treated concomitantly with GCs and GH, the GH
failed to counteract the decreased bone formation and increased bone resorption induced by protracted
treatment with a high dose of GCs (0rtoft and Oxlund, 1996).
Although continuous administration of PTH results in bone resorption, it has been established that
pulsatile administration by daily injection of low dose PTH and the PTH-related protein (PTHrP)
increases osteoblast number, bone formation rate and bone mass (Schmitt et aI, 2000). Recently it was
reported that daily injections ofPTH in mice increase the life-span of mature osteoblasts by preventing
their apoptosis (Jilka et al, 1999). This study indicated that PTH exerts its protective effect not by
stimulating osteoblast proliferation but by preventing osteoblast apoptosis. Bisphosphonates and
calcitonin also have been developed as potent inhibitors of bone resorption. As with PTH, data
indicates that inhibition of osteoblast apoptosis is the most likely mechanism of the anabolic effect of
these agents (Plotkin et aI, 1999). Thus, in vitro bisphosphonates and calcitonin exert antiapoptotic
effects on osteocytic cells and mature osteoblasts, and in vivo bisphosphonates prevent osteocyte and
osteoblast apoptosis induced by GC excess.
By increasing osteoblast lifespan, more bone formation can take place. However, none of these agents
directly stimulate osteoblast proliferation, and there is still a need for development of drugs which
increase osteoblast numbers by stimulating the precursor population.
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5.1 Vanadate
A study in 1985 involving vanadium supplementation in the drinking water of an experimental
diabetic rat model led to the discovery of vanadium's insulin mimetic and anti-diabetic potential
(Heyliger et aI, 1985). Sixteen years later, vanadium compounds have been tested extensively as
treatment for diabetes in both animals and humans. It was found in vivo that vanadium requires the
presence of insulin to elicit its effects on metabolism, suggesting that vanadium acts as an insulin
enhancer (Poucheret et ai, 1998). The general opinion is that vanadium acts through inhibition of
PTPs, that dephosphorylate the insulin receptor or post-receptor level in insulin signaling pathways
(discussed in section C). The importance of the involvement of a specific phosphatase was confirmed
with the PTP-IB knockout mice (Elchebly et ai, 1999). These mice showed increase insulin sensitivity
and lower fed blood glucose and insulin levels. The PTP-IB (-/-) were resistant to weight gain when
fed a high fat diet compared to the PTP-IB (+/+) littermates that rapidly gained weight. Theoretically,
as inhibitors of PTPs, vanadium should enhance all phosphotyrosine-dependent signals, such as those
involved in GF response (Hulley et ai, 1998). Vanadate supplementation in GC-treated rats does
prevent bone loss, increasing osteoblast numbers and bone formation parameters (Hulley et aI, 2001).
However, the precise molecular targets of vanadate in bone are not yet known.
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C. INSULIN SIGNALING
1. Introduction
Insulin is clearly important for bone health. The IRS-/- mouse develops severe osteopenia (Ogata et al,
2000), as do type I diabetic humans (Hough, 1987) and rats (Hough et aI, 1981). The insulin mimetic,
vanadium, also builds bone in the low formation state induced by glucocorticoids (GC) (Hulley et al,
2001). However, insulin mitogenic signaling in osteoblasts is not weIl described.
2. Insulin receptor
Insulin is secreted by the l3-cells of the pancreas and its primary function is to regulate glucose
homeostasis. l3-cells are sensitive to increasing blood glucose concentrations. Biological actions of
insulin are initiated when insulin binds to its cell surface receptor (Fig.ill). Variable numbers of the
receptor are expressed in almost all mammalian tissues, with the highest concentration (>300, 000
receptors per cell) being found on two of insulin's major target tissues, adipocytes and liver
(Cheatham and Kahn, 1995). However, insulin can also bind to and activate other receptors such as the
IGF-I receptor. IGF-l is produced in multiple tissues, but is secreted predominantly in the liver and
acts to stimulate tissue growth and differentiation. The insulin and IGF-l receptor are similar in
overall structure, but their binding affinity for their heterologous receptors are approximately 100-fold
less than for their own receptors (Nystrom and Quon, 1999). Itwas always believed that the mitogenic
effects of insulin were only mediated through the IGF-l receptors. However, it was proved that in
some cells insulin mitogenic signaling may be mediated by both its own and IGF-l receptors (Ish-
Shalom et al, 1997).
2.1 Structure
The insulin receptor and highly homologous IGF-I receptor are members of a family of ligand-
activated receptor tyrosine kinases (RTK) (LeRoith et aI, 1995). They are subdivided into members of
class II receptors because of the cysteine-rich motifs in their extracellular a-subunits and are
disulfide-linked heterotetramers (Ullrich and Schlessinger, 1990). The Ci2132-heterotetramerstructure
consists of two extracellular a-subunits and two transmembrane l3-subunits held together by disulfide
bonds (Navarro et aI, 1998). Although structurally and functionally related, the insulin and IGF-l
receptor modulate different responses within the cell. IGF-l has been implicated mostly in mitogenic
functions and insulin in metabolic actions.
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2.1.1 The a-subunit
The a-subunit has a molecular weight (Mr) of approximately 135, 000 Daltons and is located entirely
extracellularly (Kasuga et aI, 1982). It has an N-terminal domain responsible for high-affinity insulin
binding (Gustafson and Rutter, 1990). The subunit has a total of 37 cysteine residues encoded by
exons 3-5. Cysteine 524 is involve in a-a disulfide bonds, covalently linking two a-13 heterodimers
(Sparrowet al, 1997). Two insulin receptor isoforms exist, which arise by alternative splicing of the
mRNA. The isoforms differ in the absence or presence of exon 11, a 12-residue segment in the most
carboxy-terminal domain of the a-subunit (Sesti et aI, 1995). In the absence of insulin, the a-subunit
maintains an inhibitory influence over the tyrosine kinase in the l3-subunit, inhibiting an otherwise
constitutively active kinase (Shoelson et al, 1988).
2.1.2. The fJ-subliltit
The l3-subunit has an apparent Mr of 95,000 Daltons and anchors the receptor in the membrane
(Lënnroth, 1991). It consists of a short extracellular domain, a transmembrane domain, and an
intracellular domain that contains a tyrosine-specific protein kinase. Tyrosine kinase activity is
required for insul in action (Kasuga et aI, 1982). Three tyrosine residues, 1158, 1162 and 1163, are
major sites of autophosphorylation and comprise the kinase regulatory domain (Wilden et aI, 1992).
Both the carboxy-terminus and juxtamembrane region also contain tyrosine phosphorylation sites, but
these do not appear to be important for activation of the kinase (Cheatham and Kahn, 1995).
2.2. Insulin receptor substrate (IRS) family members
Upon ligand binding, most tyrosine kinase receptors undergo autophosphorylation, creating high-
affinity binding sites for various molecules that contain src homology-2 (SH2) domains. However,
apart from a possible role for She, these interactions are not critical for insulin signaling (Yamauchi
and Pessin, 1994). There are a number of substrates for the insulin receptor tyrosine kinase such as
insulin receptor substrate-I (IRS-I), IRS-2, -3, -4, and Gab- I that provide an interface between the
insulin receptor and downstream SH2-domain containing signaling molecules (Nystrom and Quon,
1999; Lehr et al, 2000). The IRS proteins have several features in common, including a well-
conserved pleekstrin homology (PI-I) domain, followed by a phosphotyrosine binding (PTB) domain,
that are important for efficient coupling to the activated insulin receptor (Whitehead et aI, 2000). The
PTB domain is completely absent from Gab-I but it contains a c-Met binding domain (MBD)
providing a mechanism for receptor-substrate coupling (White, 1998). The carboxy-terminal of IRS
contains mul tiple tyrosine-rich motifs that undergo phosphorylation by the insulin receptor and serve
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as docking sites for SH2-domain containing proteins. While there is considerable evidence for a direct
role of IRS-l and IRS-2 in insulin's metabolic actions, the role of IRS-3 and IRS-4 are less clear.
Results from knock-out mice indicated that IRS-l (-/-) mice have retarded growth and are insulin
resistant (Araki et al, 1994). Osteoblastic IRS-l is essential for maintaining bone turnover. Mice
lacking the IRS-l gene showed reduced proliferation and differentiation of osteoblasts and impaired
osteoclastogenesis, resulting in low-turnover osteopenia (Ogata et al, 1994). IRS-2 (-/-) mice develop
diabetes due to a combination of insulin resistance and failure to develop compensatory response to 13-
cells (Withers et al, 1998). There are also tissue- specific differences in the roles of the IRS proteins in
mediating insulin action, with IRS-l being more prominent in skeletal muscle and IRS-2 in liver (Kido
et aI, 2000). It appears that IRS-3 and IRS-4 have less prominent roles in glucose metabolism than
IRS-l and -2, raising the question as to whether these two molecules play any role in insulin and IGF
signaling (Fan tin et al, 2000; Liu et al, 1999).
3. Insulin metabolic signaling
Once insulin binds to and activates its receptor tyrosine kinase, insulin signaling pathways diverge.
One pathway proceeds through the insulin receptor substrates IRS-I and IRS-2 and depends on the
activation of the enzyme phosphatidylinositol 3-kinase (PI3-kinase). Another pathway goes through
Grb2/Sos, leading to activation of the MAP kinase (ERK) cascade. Insulin produces most of its
metabolic actions through the PI3-kinase pathway (See Fig.III).
3.1 Mediators of insulin-regulated glucose transport
A primary function of insulin is to control blood glucose concentrations by stimulating glucose
transport into target tissues such as muscle and adipocytes. Two types of glucose transporters are
responsible for glucose uptake into the body. The sodium-linked glucose transporters are mostly
localized in the intestine and kidney and are not known to be regulated by insulin (Shepherd and Kahn,
1999). Glucose uptake into all other types of tissue is accomplished by the facilitative glucose
transporters referred to as GLUTI-5 (Cheatham and Kahn, 1995). GLUT4 is the only major insulin-
regulated glucose transporter and is located primarily in adipose tissue and muscle cells. In the
absence of insulin, almost all of the GLUT4 is found in an intracellular storage pool (Holman and
Sandoval, 2001). In response to insulin a rapid increase in the rate of glucose uptake is induced. This
occurs primarily as a result of the translocation of vesicles containing GLUT4 to the plasma
membrane. The vesicles fuse with the plasma membrane, causing a 10-40 fold increase in GLUT4
concentration and the rate of glucose transport into the cell also increases (Cheatham, 2000).
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Figure III: Insulin signaling pathways. (A) Metabolic pathway: Insulin binding to
its receptor results in receptor autophosphorylation and tyrosine phosphorylation
of insulin receptor substrates (IRS). IRS associates with the regulatory subunit
ofPI3-K. PI3-K lipid products activate PDK1I2, which activates Akt/PKB. PKB
deactivates GSK-3, leading to activation of glycogen synthesis. Activation of PKB
also results in translocation ofGLUT4 vesicles to the plasma membrane.
(B) Mitogenic pathway: Other signaling molecules can associate with IRS, such as
Grb2. Grb2 is constitutively associated with Sos, which activates Ras, leading to
activation ofRaf, MEK, ERK and translocation ofERK to the nucleus. PI3-K can lie
downstream ofRas or signal to mitosis through Raf(Modified from Bevan, 2001).
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3.2 Pl I-kinase and the metabolic effects of insulin
The first downstream molecule that was shown to associate with IRS-l is PB-kinase (Sun et aI, 199I;
Folli et aI, 1992). This enzyme is composed of a lIOkDa catalytic (p 110) and a 85kDa regulatory
(p85) subunit. The p85 subunit contains two SH2 domains, through which it associates with tyrosine
phosphorylated IRS (Myers et al, 1992). This activates the catalytic function of the associated p l IO
subunit. This subunit has a lipid kinase activity which phosphorylates the D-3 position of the inositol
ring of phosphoinositides, producing phosphatidylinositol 4, 5- bisphosphate [PI-(4, 5) P2] and PI-(3,
4, 5) PJ (Ogawa et aI, 1998; Srivastava, 1998)
3.2.1 Glycogen synthesis
Protein kinase BI PKB (also known as RAC or Akt kinase) is regulated through both localization
(Andjelkovic et al, 1997) and phosphorylation (Taker and Newton, 2000). The PB-kinase lipid
products bind to the pleekstrin homology domain of PKB and function to attach cytosolic, inactive
PKB to the plasma membrane (Stokoe et al, 1997). PKB undergoes a conformational change allowing
phosphatidylinositol-dependent kinases 1 and 2 (PDK1I2), to phosphorylate and activate PKB. This
activation requires phosphorylation of serine and threonine residues. PDK 1 was shown to
phosphorylate threonine 308, while the kinase that controls serine 473 phosphorylation is still
unknown, but has been designated PDK2 (Alessi et aI, 1997). Phosphorylation of both residues is
required for full PKB enzyme activity (Hajduch et aI, 2001). Active PKB in tum phosphorylates and
inactivates glycogen synthase kinase-3 (GSK-3), leading to activation of glycogen synthase and thus
glycogen synthesis (Ueki et al, 1998; Cross et al, 1995).
Interesting findings or exceptions to the classical pathway include the activation of PKB independent
of PB-kinase. Kroner et aI., (2000) revealed in platelets a PB-kinase-independent PKB activation in
which protein kinase C (PKC)-a/p regulates the phosphorylation of serine 473 in PKBa. Threonine
450 is constitutively active and does not contribute to PKBa activation (Kroner et al, 2000). Also, in
addition to its well established role at the plasma membrane, an active PB-kinase has been shown in
nuclei of different cell types (Martelli et al, 2000). In another study intranuclear translocation of PKB
was shown (Borgatti et aI, 2000). This indicates that both PB-kinase and PKB not only act at the
plasma membrane but can also themselve move to the nucleus and affect proliferation.
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3.2.2 Glucose transport
Another important metabolic response to insulin-stimulated activation of PB-kinase is GLUT4
translocation and uptake of glucose into the cell. Besides PKB activation, the lipid products of PB-
kinase have been shown to regulate several other intracellular serinel threonine kinases, including
mTOR, p70 S6 kinase and the "atypical" protein kinase C (PKC) isoforms, PKC-A and PKC-s
(Cheatham, 2000). Of these, PKB, PKC-A and PKC-S elicit signals that can modulate GLUT4
translocation (Standaert et al, 1999; Tanti et al, 1997).
Data implicating PKB in GLUT4 translocation to the plasma membrane comes from studies involving
over-expression of constitutively activelinactive mutants of PKB in cultured cell models. In 3T3-L 1
adipocytes, overexpression of constitutively active PKB leads to increase recruitment of GLUT4 to the
cell surface (Kahn et ai, 1996). Furthermore, a dominant-negative (kinase-inactive) mutant
significantly inhibited insulin-stimulated translocation of GLUT4 (Cong et al, 1997). From the
literature it seems that PB-kinase trans locates from the cytosol to GLUT4-containing vesicles in
response to insulin (Calera, 1998). The PB-kinase lipid products recruit PKB, promoting translocation
of the vesicles to the plasma membrane and stimulation of glucose transport.
Similarly, the involvement of PKC-A and PKC-s in insulin-stimulated GLUT4 translocation has been
reported in several cell culture systems. In L6 myotubes, expression of wild-type or a constitutively
active PKC-A stimulated GLUT4 translocation (Bandyopadhyay et al, 2000). In 3T3-Ll adipocytes,
expression of kinase-inactive mutants of atypical PKCs inhibited insulin-stimulated GLUT4
translocation, but without any effect on insulin-induced activation ofPKB. (Kotani et al, 1998). These
studies indicate that GLUT4 translocation in these cells is dependent on both atypical PKCs (PKC-
Als) and PKB activation. However, although the insulin signal passes through PB-kinase, downstream
the pathway diverge into 2 independent pathways, a PKB pathway and a PKC-A pathway, and the
latter pathway contributes, at least in part, to insulin stimulated glucose uptake.
4. Insulin 111 itogenic signaling
In addition to its classical metabolic effects, insulin is a mitogen to many cell types (Lev-Ran, 1998).
Some of the pathways described below have been demonstrated to be activated in response to insulin,
and others are likely effectors, given their roles in response to other mitogens.
As already described, once activated, the insulin receptor attracts IRS 1/2 as well as She through their
PTB- or PH- domains (Sun et al, 1995; Pronk et al, 1993; White et al, 1985). SH2-containing adapter
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proteins bind to phosphorylated IRS 1/2 and She, One such signaling molecule is the growth factor
receptor-binding protein 2 (Grb2). Grb2 is an adapter protein that consists predominantly of one SH2
and two SH3 domains and has no intrinsic catalytic activity (Lowenstein et aI, 1992). SH3 domains
have specificity for proline-rich sequences (Ceresa and Pessin, 1998). Through one SH3 domain, Grb2
associates with mSos, the mammalian homolog to the Drosophila son-of-sevenless protein (Skolnik et
al, 1993; Li et al, 1993). mSos is a guanine nucleotide exchange factor (GEF) and promotes the
exchange of GDP for GTP on p21Ras (Simon et al, 1991; Sprang, 2001). Conversion to the active
GTP bound form of Ras results in activation and the ability to couple with downstream effector
molecules (Moodie et aI, 1993). GTPase activating proteins (GAPs) promote intrinsic GTP hydrolysis,
causing rapid conversion of Ras to the GDP- bound inactive conformation (Cales et al, 1988).
Hyperphosphorylation of Sos on serine/threonine residues causes dissociation of the Grb2-Sos
complex (Zhao et aI, 1998). Previous studies have suggested that, in addition to the GAPs, this is a
second negative feedback loop controlling the Ras activation/inactivation cycle. It was shown in vitro
that activation of the Raf-MEK-ERK kinase cascade generates this negative feedback signal from
MEK (ERK kinase) or a downstream kinase (Langlois et al, 1995). However, activation of Ras,
independent of the Grb2/Sos complex has also been illustrated, demonstrating that Grb2 function is
not always necessary for Ras activation (Fucini et aI, 1999).
4.1 Attachment of Ras to the plasma membrane
Ras is a member of a superfamily of small guanosine triphosphates (GTP-ases) consisting of more
than a 100 proteins (See reviews by Symons and Takai, 2001; Reuther and Der, 2000). There are four
Ras proteins, H-Ras, N-Ras, K-Ras4A and K-Ras4B. The last two are products of alternative splicing.
Ras proteins are highly homologous and 21kDa in size. They share 85% sequence identity, but all 4
proteins are 100% identical in the region important for downstream effector interaction. The only
difference in their sequence is in the carboxy-terminal region. This region contains the CAAX-motif
responsible for targeting Ras to the plasma membrane. Activation ofRas by GTP-loading is dependent
on localization to the plasma membrane (Goalstone and Draznin, 1998).
Inactive Ras is synthesized in the cytoplasm. The CAAX (the C is a cysteine, A an aliphatic amino
acid and X is a serine or methionine) tetrapeptide undergoes three post-translational modifications
(Gibbs et ai, 1997). Firstly, Ras is farnesylated. This process is catalyzed by farnesyl transferase,
causing the attachment of a l S-carbon lipid chain (C 15 isoprenoid) to the cysteine residue of the
CAAX motif (Schaber et al, 1990). After famesylation, the AAX residues are cleaved by the
endopeptidase enzyme from the endoplasmic reticulum. The final step is the methyl esterification of
the carboxy-terminal, catalyzed by carboxy-methyl transferase (Clarke et aI, 1988). In addition, Ras
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must be anchored to the plasma membrane in order to function. Hydrophobicity is conferred on H-Ras,
N-Ras and K-Ras4A by palmitoylation of an upstream cysteine. In contrast, K-ras4B has a lysine- rich
polybasic region that associates with the phosphate groups in the plasma membrane (Hancock, 1990).
These are the final steps necessary for Ras to insert into the inner leaflet of the plasma membrane
(Hancock et al, 1991).
4.2 Ras downstream effector pathways
For a long time it was believed that Ras activates a linear kinase cascade, with Raf as the immediate
downstream kinase (Fig.III). It has become clear that once activated, Ras can in tum activate a variety
of downstream signaling pathways. However, Raf was the first effector identified downstream of Ras
(Vojtek et al, 1993).
4.2.1 Raf activation- tire main effector pathway
Raf proteins have an amino-terminal regulatory domain and carboxy terminal kinase domain
(Kerkhoff and Rapp, 2001). Activation of Raf is very complex and not only requires movement to the
membrane and binding to GTP-bound Ras, but also involves the 14-3-3 proteins, heat-shock proteins
and multiple phosphorylations (Morrison and Cutler, 1997). Raf proteins are phosphorylated on
threonine, tyrosine and serine residues. Raf interaction with Ras is dependent on two domains and
binding of Ras to both is required (Drugan et aI, 1996). The Ras binding domain, binds Ras first,
followed by the cysteine rich domain (Brtva et al, 1995). The cysteine rich domain is involved in the
interaction of Raf with lipid molecules and 14-3-3 proteins (Rommel and Hafen, 1998).
It has always been reported that recruitment of Raf to the membrane and subsequent activation is
dependent on the Ras/ Raf interaction. However, Raf-I also has distinct binding domains for two
phospholipids, phosphatidic acid and phosphatidylserine (Ghosh et aI, 1996). A recent publication
indicates that recruitment of Raf is a function of phosphatidic acid, whereas the activation of Raf is
because of the interaction between Raf and the two binding domains of activated Ras (Rizzo et al,
2000).
The amino-terminal of Raf negatively regulates its catalytic activity (Cutler et al, 1998; Winkler et aI,
1998). There is evidence that Ras binding reduces this inhibitory effect. For Raf to be activated it
needs both the Ras signal and phosphorylation on serine and tyrosine residues (Mineo et al, 1997;
Marais et aI, 1997). Important phosphorylations sites includes tyrosine 340 and 341 and serine 338 and
339 (Mason et ai, 1999; Diaz et aI, 1997). Phosphorylation of serine 259 results in binding of the
scaffolding 14-3-3 proteins (Muslin et aI, 1996). Although there is still a lot of controversy on the
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exact mechanism of interaction, it is clear that 14-3-3 proteins can affect Raf activity in either a
positive or negative manner (Thorson et ai, 1998). One theory is that in resting cells, 14-3-3 proteins
are bound to Raf at serine 259, keeping it in an inactive conformation (Morrison et ai, 1993). Binding
of Ras to the Ras binding domain of Raf causes displacement of the 14-3-3 protein, giving Ras access
to the cysteine rich domain of Raf. The displaced 14-3-3 protein binds with higher affinity to serine
621 and stabilizes the active Raf (Morrison and Cutler, 1997). The other scenario is that a 14-3-3
dimer keeps Raf in an inactive state. Once localized and activated at the membrane, Raf can associate
with protein phosphatase 2A. This interaction destabilizes the 14-3-3 and phosphoserine 259
interaction, the phosphatase removes the phosphate, allowing one arm of the 14-3-3 dimer to interact
with upstream activators (Kolch, 2000).
Additional binding proteins for Raf-I are Hsp90 and Cdc37. The function of the heat shock protein,
Hsp90, seems to be stabilization of the tertiary Raf structure (Schulte, 1995). Later it was found that
Cdc37 is required for the association ofHsp90 with Raf (Silverstein et al, 1998). The exact role of the
involvement ofCdc37 is still not clear.
The three Raf isoforms (Raf-I, A-Raf and B-Raf) share Ras as a common upstream activator and
MEK as a downstream substrate (Robinson and Cobb, 1997). Activation of MEK requires
phosphorylation of two serine residues in the kinase activation loop (Yan and Templeton, 1994). This
kinase is classified as a dual-specificity kinase, since it can phosphorylate both threonine and tyrosine
residues (Dhanasekaran and Prernkumar, 1998). Of the known MEK family members, MEK 1 and 2
act on ERK.I and 2 (also referred to as p42 and p44 Mitogen-activated protein kinase or MAPK)
(Zheng and Guan, 1993). MEK 1/2 has a proline rich region in their carboxy-terminal domains that is
absent from other family members (Catling et aI, 1995). Once activated, MEKl/ 2 activate ERK1I2
through phosphorylation at a threonine and tyrosine in the - Thr-Glu- Tyr- motif (Avruch, 1998).
Activated ERKs translocate to the nucleus where they phosphorylate and activate various transcription
factors such as Elk-I and other targets leading primarily to proliferation (Cobb, 1999).
4.2.2 The Ras effector- Pls-kinase
From the literature it is clear that the lipid kinase, PB-kinase, is the second best characterized
downstream effector of Ras (See reviews Bos, 1998; Jun et al, 1999; Rommel and Hafen, 1998). As
already described, PB-kinase is important in insulin metabolic signaling. Binding of PB-kinase
regulatory subunits to activated receptor tyrosine kinases or the IRS docking proteins causes activation
of the kinase. However, ample ill vitro and in vivo findings indicate that PB-kinase can also be
activated through direct interaction with Ras-GTP (Kodaki et al, 1994; Rodriguez- Viciana et al, 1994).
This leads to activation of the lipid kinase activity of PB-kinase (Fig.III). The lipid products of PB-
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kinase not only bind to PKB (as discussed in section C3.2.1, page 16), but also to the Rho family
GTPase, Rae (Shields et aI, 2000). PB-kinase binds to the Rae GDP/GTP exchange factor, which
activates Rae, and this in tum activates nuclear factor-kappa B (NF-KB) (Cammarano and Minden,
2001 ).
PKB has multiple substrates, which it either activates or inhibits (Khwaja, 1999). Interestingly,
although certain substrates are inhibited and others activated, the function of both of these interactions
is protection of the cell against apoptosis. An example is phosphorylation by PKB of the proapoptotic
protein Bad. The scaffolding protein 14-3-3 binds to the phosphorylated region and this interaction
prevents Bad from translocating to the mitochondria where it would bind and inhibit the anti-apoptotic
proteins Bel or Bcl-xj, (Fang et aI, 1999). Phosphorylation of the substrate (eg. Bad) creates the ideal
binding site for the 14-3-3 proteins. However, binding of the 14-3-3 proteins is not always required for
this negative regulation exerted by PKB. PKB can inhibit downstream substrates, such as GSK-3.
Inactivation of GSK-3a and p is achieved through phosphorylation of serine 21 and serine 9,
respectively (Cross et aI, 1995). Substrates that are activated include Ikappa B kinase (IKK) (Ozes et
aI, 1999). The end result is the release of the NF-KB transcription factor and protection against
apoptosis, through stimulation of expression of anti-apoptotic genes (Romashkova and Makarov,
1999).
4.2.2.1. Cross-talk between Raf and Pl I-kinase
It has been shown that the Raf-MEK-ERK cascade in growth factor signaling diverges and "cross-
talks" with other pathways. In COS cells, PB-kinase inhibitors suppressed activation of both
endogenous ERK2 and Ras by low concentrations of epidermal growth factor (EGF) (Wennstrom and
Downward, 1999). They postulated that PB-kinase-sensitive events may occur both upstream of Ras
and between Ras and ERK2. Similarly, in 3T3-Ll adipocytes insulin signaling involves a wortmann in-
sensitive PIJ-kinase in the interaction between activated Ras and Raf-I kinase (Suga et al, 1997).
Further, !TI a rat skeletal rnucle cell line L6, wortmannin apart from blocking metabolic signaling
induced by insulin and insulin-like growth factcr-I at the level of GSK-3, the PB-kinase inhibitor also
prevented the activation of Raf-I (Cross et aI, 1994). All of these results suggest that PB-kinase can
signal to and activate the mitogenic Raf-MEK-ERK cascade (Fig.ITI).
In contrast, Zinunermann and Moelling (1999) found that PKB can directly phosphorylate Raf on
serine 259. The kinase activity of Raf is regulated by phosphorylation of a serine 259 residue. This
creates a binding site for 14-3-3 protein, inactivating Raf. This negative regulation of Raf by PKB
shifted the biological response in a human breast cancer cell line from growth arrest to proliferation.
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This report provided evidence for negative cross-talk between two Ras effectors at the level of Raf and
PKB (Zimmermann and Moelling, 1999).
4.2.2.2 Ras effectors regulate the cell cycle
The primary effect of Ras activation in most cell types is proliferation. Mitogenic stimulation causes
cells to exit the GO phase or resting state, enter the G 1 phase, followed by DNA synthesis (S-phase).
Positive regulators involved are the G 1 cyclin-dependent kinases (CDKs). CDK4 and CDK6 complex
with the D-type cyclins (01,02,03) and cyclin E complexes with CDK2 (Dulic et aI, 1992; Marshall,
1999). Activation of the cyclinD-Cdk4/6 and cyclinE-Cdk2 complexes promotes phosphorylation of
the retinoblastoma tumor suppressor protein (Ezhevsky et aI, 2001). This protein is associated with the
transcription factor E2F and represses its activity (Lundberg and Weinberg, 1998).
Hyperphosphorylation of the retinoblastoma protein, promotes the release of E2F and transactivation
of genes necessary for S phase entry (Dynlacht et aI, 1994; Suzuki-Takahashi et al, 1995). Negative
regulators are the CDK inhibitors (CKls) and include the INK4 family (pI6'nk4a,pI5'nk4b,p18'nk4cand
p 191nk4d) (Hirai et aI, 1995) and the CiplKip family (p2 (iPI, p27KiPI and p57Kip2) (Sherr and Roberts,
1999).
Activation of Ras is required for resting cells to enter the cell cycle at G 1 (Peeper et ai, 1997). For
cells to enter DNA synthesis, endogenous Ras function is required throughout most of G 1. Upon
mitogen stimulation of resting cells (GO), two peaks of Ras activation are present, the first
immediately when the cells enter Gland the second in mid-G 1 (Taylor and Shalloway, 1996). The
first peak is associated with the Raf-MEK-ERK pathway and the second with PI3-kinase-PKB
activation (Gille and Downward, 1999).
A relationship between Ras signaling activity and the regulation of cyclin Dl and the CDK inhibitors
has also been established. Activation of Ras is required for mitogen-stimulated up-regulation of cyclin
Dl and p21 Cipl and down-regulation of p27KiPI protein expression. Ras activation can control both
positive (cyelin Dl) and negative (p21 Cipl and p27Kip1) regulators required for GO exit, G I progression
and proliferation (Pruitt and Der, 200 I). Ras upregulation of cyclin Dl is dependent mainly on
activation of the Raf/MEK/ERK kinase cascade. For example, activation of Raf is associated with
increased cyclin Dlprotein levels and repression of the p27kip1 cyclin-dependent kinase inhibitor
(Kerkhoff and Rapp, 1997).
It is clear that once activated, Ras can activate different downstream effector pathways. Also, many
growth factor receptor pathways activate both the Ras/Raf and PB-kinase signaling cascades (Yu and
Sato, 1999). Insulin stimulated mitogenic signaling has been reported to be mostly dependent on the
Stellenbosch University http://scholar.sun.ac.za
23
Raf/MEKIERK pathway (Xi et al, 1997). In some cells, however, insulin appears to mediate
proliferation primarily through a Plê-kinase-dependent, but ERK-independent pathway. In primary
hepatocytes (Band et aI, 1999) and 3T3-Ll adipocytes (Cheatham et aI, 1994) insulin activation of
proliferation has been shown to be largely ERK-independent, and instead involves PB-kinase and
p70S6k• The latter is a 70kDa serine/threonine kinase, stimulated in response to insulin and a possible
downstream target of PB-kinase. It is therefore clear that growth factors such as insulin can stimulate
cell proliferation through multiple alternative routes, and that in osteoblasts, ERK and PB-kinase are
likely to be central effectors.
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D. AIMS OF THIS STUDY
There is a clear lack of effective anabolic agents for bone. It would therefore be helpful to explore the
exact signaling pathways used by different mitogens in bone-building osteoblasts. Insulin appears to
playa key role as an osteoblast mitogen in both developing and adult bones. We therefore set out to
examine how insulin and other growth factors signal to osteoblast proliferation, how these pathways
are negati vely affected by bone damaging glucocorticoids, and whether the insulin mimetic, vanadate,
via its inhibition of protein tyrosine phosphatase activity, would effectively combat GC damage.
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CHAPTER2
EXPERIMENTAL PROCEDURES
1. Materials
Polyclonal antibody against phosphorylated ERK (threonine and tyrosine phosphorylated, p42 and
p44) and phospho-AktlPKB antibody were from New England Biolabs, Inc. (Beverly, MA).
Polyclonal antibodies against rabbit SHP-I (100 ug/rnl), ERK (loa ug/ml), MEK (100 ug/ml), Raf-l
(100 ug/ml) and polyclonal goat PTP-IB (200 ug/rnl) were purchased from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA). Polyclonal rabbit phospho-tyrosine antibody was from Upstate
Biochemicals Incorporated (Lake Placid, NY). Reagents for ECL chemiluminescent detection,
secondary peroxidase-coupled anti-rabbit antibody from donkey, and [methyl-JH] thymidine were
from Amersham Pharmacia Biotech (UK). Immunopure protein A agarose beads were purchased from
Pierce Scientific (Rockford, Illinois). Immobilon-P transfer membrane was from the MiIIipore
Corporation (Bedford, MA). Liquid scintillation cocktail and poly-Q vials were from Beckman
Coulter. ua 126 was purchased from Promega (Madison, WI). FCS was from Delta Bioproducts
(Johannesburg, R.S.A). All other chemicals including tissue culture media, O-tetradecanoylphorbol
I3-acetate (TPA), dexamethasone, wortmannin and insulin were of the highest grade, obtained from
Sigma Chemical Co. (St. Louis, MO).
2. Cell treatments
U0126 and Wortmann in were dissolved in DMSO to 10 mM and 2 mM, respectively. If inhibitors
were added to cells, control cultures were treated with equivalent amounts of DMSO. Insulin was
dissolved in acidified water, pH=3, immediately before use. Dexamethasone and TPA were dissolved
in ethanol and DMSO, respectively. Aliquots were stored at -20°C. Sodium orthovanadate was
dissolved in sterile water immediately before LIse.
3. Tissue Culture
MBA-15.4 and MBA-15.6 mouse bone marrow stromal cells (donated by Professor S. Wientroub, Tel
Aviv University, Israel) were cultured in Dulbecco's modified Eagle's medium (DMEM). UMR-l06
rat cells (donated by Prof TI Martin, Australia) were grown in Minimum essential Eagle's medium
(MEM) and the MG-63 human preosteoblasts in MEM alpha modification. All media were
bicarbonate buffered and supplemented with 10% heat-inactivated FCS (unless serum-starved),
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100U/ml penicillin and 100 ug/ml streptomycin. For experiments, cells were lifted by scraping with a
rubber policeman, before being seeded in 24-well plates (proliferation studies), or 1Ocrn culture dishes
(immunoprecipitation), except for the UMR-I06 cells that were washed once with phosphate-buffered
saline (PBS) and trypsinized with 0.05% trypsin in 0.01% EDTA. Details of treatments are provided in
the figure legends.
4. SDS-Polyacrylamide Gel Electrophoresis (PAGE) and Westent blots
Serum-starved cells in IOcm culture dishes were treated as described, washed twice with ice-cold wash
buffer (20 mMTris, pH7.5; 100 ).lMNa3V04; 50 mM NaF; 1 mM EGTA; 1 mM levamisole; 1 mM
PMSF) and sonicated on ice in 400 ).lIof cold lysis buffer (wash buffer containing 1 ug/rnl each of
aprotinin, leupeptin and pepstatin). Cell lysates were centrifuged at 4°C (14,000 x g for 8 min) and
protein concentrations were determined using the Bradford method, with bovine serum albumin as a
standard (Bradford, 1976). Equal-protein samples were diluted in Laemmli sample buffer containing
p-mercaptoethanol and boiled for 5 min (Laemmli, 1970). Proteins were separated by SOS-PAGE on a
10% polyacrylamide gel and transferred by electroblotting to Irnmobilon-P membrane (Millipore
Corp.). Membranes were immersed in methanol for 10 sec, allowed to air dry for 15 min and blocked
in Tris-buffered saline (TBS: 20 mM Tris, pH7.5; 137 mM NaCI) containing 0.1%Tween-20 (TBS-T)
and 5% nonfat dry milk for 1 h at room temperature. Blots were washed 5 times for 5 min with TBS-T
and incubated overnight at 4°C with rabbit polyclonal ERK antibodies against p42/p44 (Santa Cruz
Biotechnology), SHP-l, Raf-I, MEK, phospho-42/44 ERK (New England Biolabs) or phospho-
AktlPKB (New England Biolabs). The membranes were rinsed in TBS-T followed by a 1 h incubation
at room temperature with the secondary antibody [anti-rabbit IgG horseradish peroxidase (from
donkey)]. The membranes were washed in TBS-T and the transferred proteins were detected using
chemiluminescence (ECL system, Amersham Pharmacia Biotech).
5. Cell proliferation
Serum-starved cells sub-cultured into 24-well plates were treated with various agents and for time
periods as described in the figure legends. In every experiment 2~lCi/well eH] thymidine (Amersham
Pharmacia Biotech) was added to the medium for the last 2 h of incubation. The plates were placed on
ice, washed twice with cold PBS before being quick-frozen at -80°C for 30 min. Cells were thawed at
room temperature and lysed in 0.1 M NaOH-O.I % SOS before adding 50% trichloroacetic acid (TCA)
for an overnight precipitation at 4°C. The pellet was washed once with cold 10% TCA, dissolved in
0.1 M NaOH and counted in Ready Gel aqueous scintillation fluid (Beckman) to obtain a
measurement of eH] thymidine incorporation during DNA synthesis.
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6. Immunoprecipitation
Serum-starved cells in 24-weII plates were treated as indicated, washed twice with ice-cold wash
buffer (20 mMTris, pH7.5; 100 11MNaJV04; 50 mM NaF; 1mM EGTA; 1 mM levamisole; 1 mM
PMSF), collected by scraping with a rubber policeman, and sonicated on ice in 400 III cold lysis buffer
(wash buffer containing 1 ug/ml each of aprotinin, leupeptin and pepstatin). Supernatants clarified by
centrifugation were incubated overnight at 4°C with 4 ug of the relevant antibody/ml lysate. Immune
complexes were collected by incubation for 2 h at 4°C with 100 III protein A agarose bead slurry. The
beads were washed three times with ice-cold PBS, solubilized in 50 III Laemmli sample buffer, boiled
for 5 min and the proteins separated by SDS-PAGE, followed by Western blotting.
7. Statistical allalysis
Results are given as the mean ± S.E.M or ± SD as indicated. Data were analyzed using GraphPad
Prism v 2.0 I (GraphPad Software, Inc.) by one-way Anova with Dunnett's Post-hoc test or one-way
Anova with Bonferroni Post-hoc for multi-group comparisons. Differences were considered
statistically significant at P<0.05.
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CHAPTER3
RESULTS
1. Insulin-induced proliferation under different serum conditions and in different osteoblast cell
lilies
The mitogenic phorbol ester TPA (l ug/rnl), and 20% FeS which is a cocktail of growth factors, are
known mitogenic stimuli for most osteoblast cell lines. These mitogens were included in Fig.IA and B
as positive controls. To determine the effect of insulin as an osteoblast mitogen, 50% confluent cells
were serum starved in 1% FeS for 24 h, prior to treatment with increasing doses ofinsuIin (0.01-10
ug/ml) for a further 24 h. DNA synthesis was measured by eH] thymidine incorporation. Although a
clear dose response was not observed in all experiments, an increase in proliferation of -70% above
control levels was seen with all 4 doses of insulin used (Fig. IA). However, this was highly variable
from experiment to experiment. This experiment was repeated, but instead of using 1% FeS, the cells
were serum starved in 0.5% FeS for 24 h prior to insulin treatment to lower the proliferation rate of
controls. As shown in Fig.IB, there was an increase in proliferation, which was maximal at 10 ug/ml,
causing an increase of -60% above control cells. It was not possible to maintain live cultures in the
complete absence of growth factor-containing serum. By lowering the serum to 0.5%, the control
thymidine incorporation was much lower and the percent increase in proliferation above control levels
was more consistent in later experiments.
To compare insulin response in a variety of osteoblast cell lines, a relatively immature MG-63 human
and the differentiated UMR-I06 rat osteoblast cell line were treated with the same insulin
concentrations (0.01-20 ug/ml). The cells were serum starved in 0.5% FeS for 24 h, followed by
insulin treatment for 24 h. Insulin stimulated proliferation in the MG-63 human cell line (Fig. IC) in a
concentration-dependent manner with the maximal increase (160%) obtained with the top three doses
1,10 and 20 ug/rnl of insulin. The mature UMR-I06 rat osteoblasts responded with less sensitivity to
insulin, producing a more modest stimulation (6-21%) of cell proliferation (Fig l.D) with 0.1-20 ug/ml
of insulin treatment when compared with controls. Based on this data, in subsequent experiments
insulin was used at a concentration of 10 ug/rnl. The younger osteoblasts (mouse MBA-I5.4 and
human MG-63) were much more insulin sensitive, compared to the more mature UMR-rat cells.
Although we did not have an immature rat cell line to test, we concluded that differentiation state was
important when looking at the effect of insulin on osteoblast proliferation.
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FIG.1. Insulin activation of proliferation in mouse preosteoblasts. Dose-response of (A, B)
MBA-15.4 mouse cell line to insulin treatment. Cells were cultured to 50% confluency and
starved overnight in medium containing 1% FCS (A) or 0.5% FCS (B). This was followed by
treatment with different concentrations of insulin as indicated for 24 h. TPA (1 j.Jg/ml)and FCS
(20%) were included as positive controls in A and B only. DNA synthesis was measured by
incorporation of PH] thymidine. Results shown are the mean ± S.E.M of eleven (A) and fifteen
(B) independent experiments expressed as percent of respective controls. *P< 0.05, **P< 0.01
compared with control; n.s: not significant compared with control (One-way Anova with
Dunnett's post-hoc).
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FIG.1 (cont.). Insulin activation of proliferation in human and rat osteoblast cell lines.
Dose-response of (C) MG-63 human and (0) UMR-1 06 rat cell lines to insulin treatment. Cells
were cultured to 50% confluency and starved overnight in medium containing 0.5% FCS (C, 0).
This was followed by treatment with different concentrations of insulin as indicated for 24 h.
DNA synthesis was measured by incorporation of [3H] thymidine. Results shown are
representative experiments performed in triplicate. Fig.1C and 0 is courtesy of Dr Y
Engelbrecht.
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2. ERK activity was induced by insulin, TPA and 20% FCS treatment in MBA-15.4 preosteoblasts
In order to evaluate the ability of insulin to activate ERK, relative to the known potent ERK activators,
TPA and FCS, serum starved MBA-15.4 cells were stimulated with optimal concentrations of
mitogens, 10 ug/rnl insulin, 100 ng/ml TPA or 20% FCS for various periods of time. Phosphorylation
ofERK was assessed by Western blots, using an antibody directed against dual-phosphorylated, active
ERK-l/2 (Fig.2A). Maximum phosphorylation of ERK was seen at the 5 min time point for all 3
mitogens. Insulin produced a more modest stimulation of ERK activity compared to TPA and 20%
FCS (80-fold vs 160-fold), and this was greatly attenuated by 60 min, whereas response to the other
mitogens remained strong. The total amount of ERK in each lane was similar, as indicated by
immunoblot analysis using an antibody to total ERK, and the fold increase in ERK phosphorylation
shown in Fig.2B was corrected to reflect active-ERK per equal ERK sample.
3. Effect of inhibition of MEK and PlI-kinase on insulin- and FCS-induced ERK activity
Next we investigated which signaling pathway activated by insulin (metabolic-, mitogenic- or other
pathway) mediates ERK activation in MBA-15.4 osteoblasts. As a positive control, experiments were
repeated with 20% FCS. The cells were pre-incubated for 30 min with a single treatment of either 10
~lM U0126, a specific inhibitor of MEK-l and -2, or 100 nM wortmannin, a PB-kinase inhibitor,
followed by short (5 and 30 min) or longer (24 h) 10 ug/ml insulin or 20% FCS stimulations. At 10
)-tM, U0126 completely inhibited insulin-induced phosphorylation of ERK-l/2 at 5 min and at 30 min
(Fig.3A). FCS-induced ERK phosphorylation was inhibited by 70% at 5 min and at 30 min of
mitogenic stimulation (Fig.3C). After 24 h, U0126 was still inhibitory, reducing insulin- and FCS-
stimulated ERK activity by -90% (Fig.3B) and -70% (Fig. 3D), respectively. Since activation of the
PB-kinase pathway is associated with proliferative signaling by Ras, we also investigated whether this
pathway was involved. Pretreatment for 30 min with 100 nM wortmannin decreased ERK activity by
60% after 5 min and almost completely after 30 min of insulin treatment (Fig.3A). Twenty-four hours
later, insulin-stimulated ERK activity was still 42% lower in wortmannin treated samples, than in
insulin-stimulated samples that received no wortmann in (Fig.3B). However, wortmann in did not
significantly affect FCS-stimulated ERK activity at the shorter time periods (Fig.3C), or inhibited
ERK activity more slowly, since a 46% reduction in ERK activity was seen 24 h later. This result
indicates that activation of ERK in response to insulin and 20% FCS is strongly MEK dependent. A
wortmannin sensitive PB-kinase pathway was clearly involved in ERK response to insulin stimulation
at both shorter and longer time periods, whereas wortmannin only visibly inhibited FCS-induced
activation of ERK after 24 h.
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FIG.2. Activation of ERK-1/2 by various mitogenic stimuli. Subconfluent MBA-15.4 cells
were cultured overnight in medium containing 1% FCS. Cells were treated with 10 !lg/ml
insulin, 100 ng/ml TPA or 20% FCS for 5, 10 or 60 min, respectively. In order to measure
ERK activity of the samples, cells were harvested and lysed and active or total ERKs in
equivalent concentrations of total lysate protein were visualized by Western blot analysis
using an anti-active ERKp421p44-specific antibody or a p42/p44 ERK antibody (A,
representative blof). B, represents relative active ERK levels quantified by densitometry of
immunoblots. Relative active ERK levels in control cells (no treatment) was given a value
of 1.
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FIG.3. Inhibition of insulin-induced ERK activation by U0126, a MEK inhibitor compared to
partial impairment of ERK activity by wortmannin, a Pl3-kinase inhibitor. Subconfluent
MBA-15.4 cells were cultured overnight in medium containing 1% FCS. The cells were pre-
incubated for 30 min in the presence or absence of 10 J..lMU0126 or 100 nM Wortmannin prior to
10 J..lg/mlinsulin (A,B) treatment for 5 and 30 min (A) and 24 h (B), respectively. Cells were
harvested and lysed and ERK activity was visualized by Western blot analysis using an active
ERKp42/p44-specific antibody. In the top panels (A, B) a representative Western blot is shown.
The bottom panels represents averaged data of relative active ERKp421p44 levels of three (A)
and one (B) independent experiment(s) quantified by densitometry. Relative active ERK levels in
control cells (no treatment) was given a value of 1.
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FIG.3 (cont.). Inhibition of 20% FCS-induced ERK activation by U0126, a MEK inhibitor
compared to no or partial impairment of ERK activity by wortmannin, a Pl3-kinase
inhibitor. Subconfluent MBA-15.4 cells were cultured overnight in medium containing 1% FCS.
The cells were pre-incubated for 30 min in the presence or absence of 10 J.l.MU0126 or 100nM
Wortmannin prior to 20% FCS (C,D) treatment for 5 and 30 min (C) and 24 h (D), respectively.
Cells were harvested and lysed and ERK activity was visualized by Western blot analysis using
an active ERKp421p44-specific antibody. In the top panels (C,D) a representative Western blot is
shown. The bottom panels represents averaged data of relative active ERKp42/p44 levels of one
(C,D) independent experiment quantified by densitometry. Relative active ERK levels in control
cells (no treatment) was given a value of 1.
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4. AktIPKB activation by insulin is Pl l-kinase-dependent and wortmannin sensitive
To ensure that under the experimental conditions used, wortmannin did indeed inhibit PIJ-kinase,
activation of Akt/PKB by PIJ-kinase was examined in the presence or absence of wortmannin.
Western blots were then performed using an antibody directed against phosphorylated, active
AktlPKB. MBA-15.4 cells were treated for various lengths of time with lOug/ml insulin, following 30
min pretreatment with 100 nM wortmannin. At 10 ug/ml, insulin induced a rapid activation of
AktlPKB with a peak occuring at 30 min (Fig.4A). AktlPKB activation was still detectable at 24 h
(Fig.4B). As shown in Fig.4A and B, AktlPKB phosphorylation by insulin was dramatically reduced
by wortmannin at 5, 10 and 30 min and even after 24 h. This confirms that PIJ-kinase is an upstream
mediator of insulin- induced AktlPKB activation in MBA-15.4 preosteoblasts, and that we were using
wortmannin at the correct concentration and for a suitable time.
5. FCS-stimulated proliferation is MEK-depelldent and Pll-klnase-independent, whereas insulin-
stimulated cell proliferation is MEK- ami Pls-kinase- independent in mouse preosteoblasts
Inhibitors like UO126 and wortmannin are able to block various aspects of insulin action. Given the
effect of the two inhibitors on ERK activity (Fig.3), we next studied the effect of U0126 and
wortmannin on proliferation stimulated by insulin and 20% FCS in MBA-15.4 cells. Wortmannin, the
PIJ-kinase inhibitor had no effect on insulin- or 20% FCS- induced proliferation (Fig. SA and B). As
expected, the MEK inhibitor, U0126, strongly decreased proliferation in response to 20% FCS. In
sharp contrast, insulin-stimulated activation of proliferation was unaffected by MEK inhibition, and in
fact, in many experiments, an apparent increase was observed (Fig.SA). This increase was not
statistically significant in the small number of repeats presented here, but is interesting because it
suggests the existence of a negative feedback mechanism and therefore warrants further investigation.
This result raised the question of possible novel pathways being involved in insulin signaling in
osteoblasts. To investigate this further, a combination of the two inhibitors was used, blocking both
MEK- and PI3-kinase- mediated signals (Fig.SB). Insulin stimulated proliferation was completely
unaffected by MEK inhibition or PIJ-kinase inhibition or (diagonal hatched bars) a combination of
the two. In contrast, U0126 inhibited FCS-stimulated proliferation by -50%. Wortmann in had no
effect alone or in combination with UI026 (diagonal hatched bars). It is therefore evident that insulin-
stimulated proliferation is not dependent on ERK or PIJ-kinase signaling, while proliferation in
response to 20% FCS is completely MEK-dependent (See Fig.13 in discussion) in the mouse MBA-
15.4 preosteoblast cell line.
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FIG.4. Inhibition of insulin-induced AktJPKB activation by wortmannin, a Pl3-kinase
inhibitor. Subconfluent MBA-15.4 cells were cultured overnight in medium containing 1%
FCS. Cells were pre-treated for 30 min with or without 100 nM wortmannin (A, B) for 30 min
followed by insulin treatment for various lengths of time i.e. 0, 5, 10 or 30 min (A) or 24 h
(B). Cells were harvested and lysed and active AktIPKB was visualized by Western blot
analysis using an active AktlPKB-specific antibody. In the top panels (A-B), a representative
Western blot is shown. The bottom panels represent relative AktlPKB levels quantified by
densitometry of immunoblots. Relative Akt IPKB levels observed in cells at time 0 was
defined as 1 (control).
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FIG.5. MEK inhibition by U0126 blocks 20% FeS but not insulin-induced proliferation,
while no alterations in proliferation by the Pl3-kinase inhibitor, wortmannin were
observed. 50% confluent cells were cultured overnight in medium containing 0.5% FCS.
Cells were pre-cultured in the presence or absence of 10 ~lM U0126 or 100 nM wortmannin
alone (A,B) or a combination of the two inhibitors (B, diagonal hatched bars), prior to a
further 24 h treatment without (control) or with 10 Ilg/ml insulin or 20% FCS (A,B). DNA
synthesis was measured by [3H] thymidine incorporation. Results represent the mean ±
S.E.M. of nine (A) and three (B) independent experiments and are expressed as percent of
respective control. In (B) treatment with FCS was performed in one experiment. (A), n.s: not
significant compared with insulin, #n.s: not siginificant compared with 20% FCS, *P<0.05
compared with 20% FCS. (B), n.s: not significant compared with insulin (One-way Anova
with Bonferroni post-hoc for multi-group comparison).
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6. Insulin mediated proliferative signaling was independent of cell maturity, but was different in
mouse and human osteoblasts
Since the concentration of UO126, effective for inhibition of ERK activity, did not inhibit insulin-
stimulated proliferation, we investigated two higher doses. MBA-15.4 (Fig.6A) and MBA-15.6
(Fig.6B) mouse osteoblasts were stimulated with 20% FCS or 10 ug/ml insulin after pretreatment with
increasing doses of UOl26 (l0-30!J.M). Proliferation was measured by eH] thymidine incorporation.
In the mouse, MBA-15.4 cells, pre-incubation with UOl26 completely inhibited the mitogenic effect
of 20% FCS in a dose dependent-manner (horizontal hatched bars), without any effect on insulin-
mediated proliferation (Fig.6A, black bars). To investigate whether this was age and stage dependent,
we compared the relatively immature MBA-I5.4 osteoblast cell line (Fig.6A) with the more
differentiated MBA-15.6 mouse osteoblast cell line (Fig.6B). UOI26 again had no effect at all on
insulin-stimulated proliferation, while markedly inhibiting FCS-induced proliferation. To determine
whether this finding was species-specific, a UO126 dose-response curve for inhibition of insulin-
induced proliferation was performed in the MG-63 human osteoblast cell line (Fig.6C). At 10, 20 and
30~lM concentrations, UO126 did inhibit insulin-induced proliferation in the human osteoblast cell
line. While not obviously toxic to the cells, the inhibitor also reduced basal DNA synthesis. These
results suggest that there may be species differences in insulin mitogenic signaling.
7. Insulin mitogenic signaling in human osteoblasts is dependent on ER/( and Pl.I-kinase
Although UO126 did inhibit human osteoblast proliferation in response to insulin, this inhibition was
not as severe as controls at all three doses tested. We therefore suspected that insulin signaling in the
MG-63 cell line might be less ERK-dependent than responses to other mitogens. We compared
proliferation in response to I0 ug/ml insulin versus 100 ng/ml TPA in the absence or presence of 10
!J.MUO126. Inhibition of MEK with UO126 almost completely abolished TPA-stimulated proliferation
and also severely inhibited baseline growth in 0.5% serum (Fig.7 A). However, insulin-stimulated
proliferation was only inhibited by half, indicating the possible involvement of a second pathway.
Alternatively, there may be a drug effect ofUOl26 which accounts for the apparent insulin decrease,
while the 0.5% FCS and TPA inhibition is due to both a drug effect and MEK inhibition. TPA was a
stronger mitogen than insulin, stimulating proliferation to 210% of control levels, compared with
170% stimulation by insulin. We therefore tested the involvement of PB-kinase by inhibiting it with
100 nM wortmannin alone or in combination with 10 !J.M UOl26 (Fig.7B). As before, insulin-
stimulated proliferation was only partially inhibited by UOI26. Wortmannin alone had a similar effect.
However, in combination, UOI26 and wortmann in completely abolished cell proliferation, suggesting
that the MEK and PB-kinase pathways separately and additively account for human osteoblast
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FIG.6. Comparison of immature vs mature mouse osteoblast and mouse vs human
osteoblast responses to blockade of MEK by increasing doses of U0126. 50% confluent
cells were cultured overnight in medium containing 0.5% FCS. MBA-15.4 immature mouse
(A), MBA-15.6 mature mouse (B) and MG-63 immature human (C) osteoblast cells were pre-
treated for 30 min with increasing concentrations of U0126 (0, 10, 20 or 30 ~IM) followed by
20% FCS (A, B) and 10 ~lg/ml insulin (A-C) treatment for a further 24 h. DNA synthesis was
measured by [3H] thymidine incorporation. (A-C) Results shown are the mean S.D. of two
independent experiments, each performed in triplicate and are expressed as percent of
respective control.
Stellenbosch University http://scholar.sun.ac.za
B 200
160 n=1c ___
0'"
ii ~120..._x
2 E
=0. 80o (.)..._~
0.
40
0
Control Insulin
(10 !Jg/ml)
TPA
(100 ng/ml)
40
~ + U0126 (10 !JM)
!;;I + Wortmannin (100 nM)
~ + U0126 + Wortmannin
FIG.? Insulin mitogenic signaling in human osteoblasts is depended on two separate
pathways. 50% confluent MG-63 cells (A,B) were cultured overnight in medium containing 0.5%
FCS. Cells were pre-treated for 30 min with or without 10 flM U0126 (A,B) or 100 nM
wortmannin (B) alone, or a combination of the two inhibitors (B, diagonal hatched bars). This
was followed by a further 24 h treatment without (control) or with 10 ~lg/ml insulin or 100 ng/ml
TPA (A,B). DNA synthesis was measured by [3H) thymidine incorporation. (A), Results represent
the mean ± S.E.M. of four separate experiments, each performed in triplicate and are expressed
as percent of respective control. (B), Shown is a representative result performed in triplicate.
***P<0.001 (One-way Anova with Bonferroni post-hoc for multi-group comparison).
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response to insulin (See Fig.16 in discussion). In contrast, TPA-induced proliferation was completely
inhibited by UOl26 alone and by the combination (diagonal hatched bars), but was only partially
inhibited by wortmann in alone. This indicates that all proliferative signals, including PB-kinase
signals, converge on ERK and therefore TPA proliferative signaling was completely blocked by MEK
inhibition (See Fig.15 in discussion).
8. Dexamethasone inhibits insulin-stimulated cell proliferation
Under most mitogenic conditions, Dex pretreatment inhibits MBA-15.4 and MG-63 osteoblast cell
proliferation. We investigated the effect of Dex specifically on insulin-induced proliferation of a
mouse preosteoblast cell line, MBA-15.4. Cells were serum starved in 1% FCS for 24 h. Following
repeated experiments with this cell line (as published in Hulley et aI, 1998) we had established that
these cells are increasingly inhibited by 10-8 to 10-6M Dex, with 10-5 M being toxic and 10-6M the
most inhibitory dose. Note that this experiment was done before changing the experimental conditions
from serum starving in 1% to serum starving in 0.5% FCS as explained in the results ofFig.1A. Cells
were pretreated with 10-6M Dex for 24 h (total Dex treatment was 48 h) before addition of insulin for
a further 24 h culture period, followed by CH] thymidine incorporation. The dose-dependent increase
in proliferation in the insulin-stimulated MBA-15.4 cells (Fig.8, open bars) are consistent with the
result obtained in Fig.l A. Insulin treatment resulted in a 21-45% increase in DNA synthesis.
Pretreatment with 10-6M Dex for 24 h (Fig.8, black bars) before stimulation with insulin, caused a
partial, but not significant inhibition of proliferation at all insulin concentrations. This result indicates
that in addition to inhibiting proliferation of exponentially growing cells, Dex pretreatment also
inhibited insulin-stimulation of cell proliferation in a preosteoblast cell line, MBA-15.4. However, the
decrease in proliferation caused by 48 h Dex treatment was weak and variable, and in subsequent
experiments we therefore used 72 h Dex treatments.
9. Effect 011 osteoblast proliferation of inhibition of protein tyrosine phosphatases (PTPs) by sodium
orthavanadate
From our previous work (Hulley et ai, 1998) we know that when cells grown in low serum medium
are directly stimulated with the mitogenic phorbol ester, TPA (100 ng/ml), 10-6 M Dex causes a 35%
average decrease in proliferation over 48 h. Concomitant treatment with 1 or 2 doses of sodium
orthovanadate over the course of 48 h restored proliferation to between 80-86% of TPA-stimulated
levels. A repeat experiment in the MBA-15.4 cells (Fig.9A), indicate a Dex-induced (l0-6M) decrease
in proliferation of 43%, which was restored to -80% ofTPA-stimulated levels by concomitant sodium
orthovanadate (l0-6 M) treatment over 48 h, confirming the previous result. Sodium orthovanadate is
an inhibitor of tyrosine phosphatase activity, indicating that Dex could function by increasing PTP
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FIG.8. Dexamethasone inhibits insulin-induced MBA-15.4 preosteoblast cell
pronteration. 50% confluent MBA-15.4 cells were starved overnight in medium
containing 1% FCS. Cells were pre-treated with 10-6 M Dex (bfack bars) for 24 h where
indicated prior to stimulation with different doses of insulin (0.01-10 !lg/ml) for a further
24 h. DNA synthesis was measured by [3H] thymidine incorporation. Result shown
represents the mean ± S.E.M. of six separate experiments, each performed in
triplicate and expressed as percent of respective controls. n.s: not significant when
compared to treatment with insulin alone for each respective concentration used (One-
way Anova with Bonferroni post-hoc for mufti-group comparison).
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FIG.9. Sodium orthovanadate reverses inhibition by Dex of TPA- and 10% FeS-
induced cell proliferation. Cells were cultured until 50% confluent followed by
overnight serum-starvation in 0.5% FCS. In A, the cells were pretreated with Dex
(10-6 M) alone or Dex combined with 10-6M sodium orthovanadate (horizontal hatched
bars) for 24 h prior to TPA (100 ng/ml) treatment for 24 h. In B, the culture medium
was replaced with fresh medium containing 10% FCS and the cells were treated with
Dex (10-6 M) or sodium orthovanadate (10-6 M) alone, or Dex combined with sodium
orthovanadate for 24 h. DNA synthesis was measured by [3H] thymidine
incorporation. Results shown includes a representative experiment performed in
triplicate (A) or the mean ±S.E.M. of three (B) separate experiments expressed as
percent of respective controls. Fig.9B is courtesy of Dr Y Engelbrecht. (A), **P<O.01,
***P<0.001 compared with TPA treatment, ## P<0.01 compared with TPA plus Dex
treatment. (One-way Anova with Bonferroni post-hoc for multi-group comparison). (B),
**P<0.01 compared with control, n.s. not significantly different to control (One-way
Anova with Dunnett's post-hoc).
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FIG.9 (cont.). Sodium orthovanadate had no effect on Dex-impaired insulin
stimulation of proliferation. Cells were cultured until 50% confluent followed by
overnight serum-starvation in 0,5% FCS. In C and 0, the cells were pretreated with
Dex (10-6 M) plus one (C) or two (D) doses of sodium orlhovanadate (10-6 M) for 48 h
prior to insulin (10 ~lg/ml) treatment for a further 24 h. DNA synthesis was measured
by [3H] thymidine incorporation. Results shown are the mean ±S.E.M. of three (C, D)
separate experiments expressed as percent of respective controls. (C, D), #P<0.01,
#n.s: not significant, compared with Dex; **P<0,001, *P<0.05, n.s: not significant,
compared with insulin plus Dex (One-way Anova with Bonferroni post-hoc for multi-
group comparison).
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levels or PTP activity relative to kinase activity. This was tested further in another preosteoblast cell
line, MG-63 human cells. Dex treatment of subconfluent MG-63 cells growing in 10% FCS inhibited
proliferation by ~25%. As shown in Fig.9B (horizontal hatched bars), concomitant treatment with
sodium orthovanadate (10.6 M) completely reversed the Dex-induced inhibition, compared to untreated
rapidly growing control cells. Therefore proliferation of osteoblasts in response to both TPA and the
cocktail of growth factors in FCS was inhibited by 48 h Dex treatment, and inhibition of PTPs
effectively reversed this effect. We therefore set out to test the involvement of PTPs in Dex-mediated
inhibition of insulin-stimulated proliferation. Culturing serum-starved MBA-15.4 cells in Dex for 48 h
had an inhibitory effect, however 48 h Dex pretreatment before 24 h insulin treatment caused a 38%
(Fig.9C) and 49% (Fig.9D) decrease in proliferation. Concomitant treatment with 1 (Fig.9C) or 2
doses (Fig.9D) of 10.6M sodium orthovanadate over 72 h failed to restore Dex-inhibited proliferation.
Dex treatment for 72 h caused a very severe reduction in osteoblast proliferation. Sodium
orthovanadate was unable to reverse this, so PTPs are unlikely to be involved. However, since sodium
orthovanadate acts transiently and reversibly, it might be able to reverse a weaker inhibition by Dex. It
is apparent in Fig.9C that Dex treatment also inhibited growth of cells under serum-starved conditions,
and that insulin partially reversed this. However, this apparent rescue was not significant in Fig.9D
and neither vanadate on its own or in combination with insulin was able to reverse this effect of Dex.
JO. The PTP, SHP-J co-immunoprecipitates with ERK, MEK and Raf
Since Dex inhibited FCS- and TPA- stimulated cell proliferation, which was partially corrected by
treatment with the PTP inhibitor, sodium orthovanadate, we were interested in the mechanism
whereby Dex acts. One possibility could be that Dex may either upregulate PTP levels or PTP activity.
To investigate the involvement of possible GC-sensitive PTPs, and their substrates, MBA-15.4 mouse
cells were incubated in the presence or absence (controllysates) of 10-7M Dex. Cells were lysed and
co-immunoprecipitations were performed as described in the experimental procedures. The PTP, SHP-
1 has been implicated as a negative regulator of the insulin receptor (Bousquet et aI, 1998) and can be
upregulated by GCs (CambiJlau et al, 1995). SHP-l co-immunoprecipitated with ERK (Fig. lOB),
MEK (Fig.l OD) and Raf (Fig.lOF), suggesting that SHP-l may be an important regulator of osteoblast
proliferation. SHP-l requires association with tyrosine phosphorylated proteins for activation. MEK is
not tyrosine phosphorylated but rather serine phosphorylated, suggesting that SHP-l association with
substrates in the mitogenic cascade is due to the formation of a complex.
JJ. The PTP, PTP-JB co-immunoprecipitates with ERK and MEK but not Raf
The literature provides considerable support for a physiological role for PTP-lB in the negative
regulation of the insulin action pathway (Goldstein et aI, 2000). To further investigate the involvement
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Fig.10. Co-immunoprecipitation of SHP-1 with ERK, MEK and Raf-1 in MBA-15.4
preosteoblast cells following Dex treatment. The cells were grown with 10% FCS
until 50% confluent, and then cultured for a further 48 h in fresh 10% FCS medium
(control lysate lane 1), some containing 10-7 M Dex (lysate lane 2 and 3). Cells were
lysed and subjected to immunoprecipitation using anti-ERK (A,B), anti-MEK (C,D) and
anti-Raf (E,F) antibodies, coupled to protein A agarose beads. Beads were washed,
boiled in sample buffer to release protein and proteins were analysed by Western
Blotting using antibodies for ERK, MEK, Raf and SHP-1 (as indicated) and detected
by ECl enhancement and chemiluminescence. lysate lanes in (F) were overexposed
to detect relatively low levels of Raf-1 (lP, immunoprecipitation; IB, immunoblotting;
HC, IgG heavy chain, Mr 50kDa).
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Fig.11. Co-immunoprecipitation of ERK and MEK with PTP-1 B in MBA-15.4
preosteoblasts following Dex treatment. The cells were grown with 10% FCS until 50%
confluent, and then cultured for a further 48 h in fresh 10% FCS medium (control lysate lane 1),
some containing 10-7 M Dex (lysate lane 2 and lP). Cells were lysed and subjected to
immunoprecipitation with anti-PTP-1 B (A, B, C) and anti-Raf (D, E) antibodies. Immunoblots
were probed with antibodies to ERK, MEK and Raf (as indicated). Lane 3 is an open lane in
C,D and E. (JP, immunoprecipitation; IB, immunoblotting; HC, IgG heavy chain, Mr 50kDa).
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of possible vanadate-sensitive PTPs in osteoblast mitogenic signaling, we repeated the above
experiment, looking at PTP-!B as a candidate. ERK (Fig.IIA) and MEK (Fig.IIB), but not Raf
(Fig.lIC), co-immunoprecipitated with PTP-lB. Once again, MEK cannot serve as a direct substrate
for PTP-!B, therefore this indicates multiprotein complex formation. To confirm that the 7lkDa
protein seen in Fig.! OE corresponded to Raf-I and also to check sensitivity of the technique, cells
were treated with 1O-7M Dex, immunoprecipitated with anti-Raf antibody and immunoblotted with
anti-Raf (Fig.lID) and anti-ERK (Fig. I IE) antibody. Although we failed to show that PTP-lB
associates with Raf-I, this result demonstrated that Raf-I is present (Fig.lID) and that our antibody is
active. ERK cannot serve as a substrate for Raf-I, and yet the two kinases co-irnmunoprecipitated.
This gave further confirmation that the kinases immunoprecipitated as a complex.
12. SHP-I associates with active, tyrosine phosphorylated ERK
In Fig.lOB, we have shown that SHP-I co-immunoprecipitates with ERK, thus indicating that this
phosphatase may play an important role in the down-regulating of preosteoblast proliferation. Using
an antibody that detects active, tyrosine phosphorylated ERK-1I2 we found that ERK does co-
immunoprecipitate with SHP-l under the mitogenic conditions used (5 min, 20% FCS treatment,
Fig.12A and B). This indicates that SHP-I associates with active ERK and may dephosphorylate it,
suggesting that it could playa role in the inhibition of preosteoblast proliferation. In Fig.12.C and D,
we immunoprecipitated with an antibody that detects all tyrosine phosphorylated proteins. In the
presence of 20% FCS, p42 and p44 ERK is strongly phosphorylated on both tyrosine and threonine
residues (Fig.12D, lane 2). Fig.12D indicates that the anti-active ERK antibody specifically detected
ERK tyrosine residues. Although very low levels of protein were detected in the immunoprecipitation
compared to treated control lysates, active ERK was present, confirming that SHP-! associates with
active, tyrosine phosphorylated ERK (Fig.12D).
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Fig.12. Association of SHP-1 with active, tyrosine phosphorylated ERK-1/2. MBA-
15.4 cells were grown in 10% FCS until 50% confluent, then serum starved in 1% FCS
for 24 h, and were left untreated (control lysate lane 1) or stimulated with 20% FCS for 5
min (lysate lane 2 and lP). Ceillysates were subjected to immunoprecipitation by either
anti-SHP-1 (A, B) or anti-phosphotyrosine antibodies (C, D) and proteins detected,
following Westem blotting, with either anti-active ERK (B, D) or ERK (A, C) antibodies.
(lP, immunoprecipitation; IB, immunoblotting; HC, IgG heavy chain, Mr 50kDa).
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CHAPTER4
DISCUSSION
In mammals insulin functions as a mitogen for many cells e.g. epidermal cells, developing neurons
and symphathetic neuroblasts, preadipocytes and capillary endothelial cells (Lev-Ran, 1998). Insulin
also seems to be an important osteoblast mitogen. Insulin deficiency in Type I diabetes in humans
(Mathiassen et al, 1990; Hough et al, 1987) and rats (Hough et al, 1981; Reddy et al, 2001) causes
severe osteopenia. In contrast, there is still a lot of controversy about bone mass changes in insulin
resistant or type II diabetes patients. Bone mineral density in these individuals could be increased,
decreased (Buysschaert et aI, 1992) or unchanged (Sosa et al, 1996) compared to sex-and age-matched
subjects (Piepkorn et aI, 1997). However, several findings indicate that overweight type II diabetics
have a normal or increased bone mineral density (Jensen et al, 2001). Protection against osteopenia
might be due to increased production of estrogen in the subcutaneous fat tissue, the stress of weight
bearing on the skeleton or the high circulating levels of insulin serving as an osteoanabolic agent
(Barret-Connor and Kritz-Silverstein, 1996). The insulin mimetic, vanadium, has been shown to
protect against the bone damaging effects of steroid treatment in vitro (Hulley et al, 1998) and in vivo
(Hulley et al, 2001). A critical role for insulin signaling in osteoblasts has recently been demonstrated
in the IRS-1 knockout mouse. IRS-l deficient mice showed impaired proliferation and differentiation
resulting in low-turnover osteopenia (Ogata et al, 2000). Osteoblastic IRS-l is thus important for
maintaining bone turnover, further confirming the importance of insulin as a bone mitogen. However,
the mitogenic signaling pathways used by insulin in osteoblasts remain poorly described. Therefore,
the aim of this study was to investigate the effect of insulin on proliferation, to map out the potential
signaling targets of insulin, to look at the effects of glucocorticoids on insulin-induced osteoblast
proliferation and then to examine whether the insulin mimetic, vanadate, would effectively combat GC
damage.
Selection of experimental system
To determine whether insulin can stimulate osteoblast proliferation, eH] thymidine incorporation was
measured in different osteoblast cell lines. This was done in both relatively immature (MBA-15.4
mouse and MG-63 human), more mature (MBA-I5.6 mouse) and differentiated (UMR-106 rat)
osteoblast cell lines. These are all well characterized osteoblast cell lines, expressing different levels of
osteoblast differentiation markers. The mouse marrow derived MBA-15.4 cells produces low levels of
alkaline phosphatase and PTH receptors compared to MBA -15.6 osteoblasts expressing high alkaline
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phosphatase activity and levels of PTH receptors (Fried et aI, 1993). The human MG-63 osteosarcoma
preosteoblasts express TGF -~- and 1,2S-dihydroxyvitamin D3- inducible alkaline phosphatase activity
(Clover and Gowen, 1994; Bonewald et al, 1992). The rat osteoblast-like osteosarcoma cell line UMR-
106 express high levels of receptors for vitamin D, GH, leukemia inhibitory factor and PTH (Martin et
aI, 1979). Insulin stimulated a marked increase in proliferation in the less differentiated MBA-lS.4, -
15.6 and MG-63 cell lines. Although a wide range of insulin concentration was used, the mature
UMR-I 06 cells was not very insulin responsive and showed a weak increase in proliferation. Possible
explanations are that the proliferative potential of these bone cells in response to insulin correlates
with their stage of differentiation, with the immature cells being more insulin responsive than the more
differentiated cells. However, these are spontaneously transformed cell lines with defects in their
proliferative control pathways. They never stop growing, unlike normal osteoblasts, and all results
must be interpreted with this in mind. Differences observed in response to insulin represent differences
in transformation processes between cell lines, but since all three immature cell lines were more
responsive to insulin than UMR-I06 cells, it is possible that insulin responsive pathways are up-
regulated in younger cells. This could be due to increased numbers ofIR or IGF receptors, or elevated
levels of IRS-I. The insulin concentrations used were between 0.01-10 ug/ml (1.74 nM-1.74 11M).
Although, commonly used in the literature at 100 nM, we were not sure how much of the insulin
reached the cells and therefore used a wide range of concentrations. Normal fasting plasma insulin
levels in rats (Hough, 1981) and humans (Greenspan and Strewler, 1997) averages 0.4 ng/ml
(69pmol/L), and can go up to 4 ng/ml (690pmol/L) after standard meals. The doses that we used were
therefore relatively high compared to normal plasma insulin levels.
Insulin-induced proliferation of the MBA-15.4 immature mouse osteoblast eel/line
The MBA-IS.4 mouse preosteoblastic cell line was strongly insulin sensitive. The phorbol ester TPA
and 20% FCS were included as positive controls. Both of these mitogens markedly increased
proliferation above control levels. However, insulin increased proliferation was comparable to TPA-
induced DNA synthesis. We also established that although the increase in proliferation in response to
different insulin concentrations in 1% serum conditions was comparable to the increase seen when
serum starving in 0.5% FCS, the lower serum conditions produced more consistent results.
Insulin can activate proliferation through both the Raf-MEK-ERK cascade, or through the initial
component of the metabolic pathway comprising IRS-l and PB-kinase. Therefore the next question
was whether the same signaling pathways are involved in insulin-induced proliferation in osteoblasts.
To determine this, two specific inhibitors, U0126, a MEK-l and -2 inhibitor, and wortmannin, a PI3-
kinase inhibitor, were used to establish the pathway by which insulin signals to proliferation. Increased
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proliferation in response to 20% FCS was completely MEK-dependent and PB-kinase-independent. A
completely unexpected finding was made when insulin signaling to proliferation was completely
unaffected by inhibition of both MEK and PB-kinase activation in MBA-15.4 preosteoblasts. This
was repeated and confirmed 18 times in triplicate. Interestingly, although a resistance to MEK-
inhibition was always observed, in 6 independent experiments an increase in proliferation was also
seen when cells were treated with a combination of insulin and the MEK inhibitor, U0126. This was
investigated further by using the two inhibitors in combination, thus inhibiting both MEK and PI3-
kinase at the same time. With 20% FCS, using a combination of the two inhibitors was the same as
inhibiting MEK alone which confirmed that FCS-induced stimulation of DNA synthesis was routed
through the MEK-ERK pathway (Fig.13). However, the two inhibitors alone or in combination failed
to have an effect on insulin-induced cell proliferation. These observations indicate that insulin-induced
DNA synthesis in MBA-15.4 mouse preosteoblasts does not involve MEK-ERK or PB-kinase
activation, and suggest the involvement of an alternative pathway.
The resistance of insulin-induced proliferation to inhibition and also the increased proliferation that we
frequently observed when blocking MEK may indicate that there is a negative feedback signal at the
level of or downstream of MEK (Fig.14). When MEK is inhibited, this feedback signal is removed,
allowing increased proliferation via an alternative pathway. Reports indicate that insulin activation of
ERK causes hyperphosphorylation of Sos, promoting dissociation of constitutively bound Grb2-Sos
complexes (Goalstone and Draznin, 1998). Dissociation of Grb2-Sos results in the desensitization of
Ras to prolonged activation of growth factor stimulation, whereas MEK inhibition blocks this event,
resulting in prolonged Ras activation (Langlois et ai, 1995). This may indicate that in MBA-15.4s,
insulin signals through a non-MEK, non-PI3-K Ras-dependent pathway.
In the literature U0126 is commonly used at 10 ~lM. Just to verify that the concentration ofUOl26 was
optimal, we used two to three times higher concentrations. In the MBA-15.4, FCS-induced osteoblast
proliferation was potently inhibited by 10 ~M U0126 and showed a further dose-dependent sensitivity
to MEK-inhibition. Insulin-induced DNA synthesis was unaffected by an increase in the concentration
of the inhibitor. From this result we concluded that the time of treatment and the dose of UO126 was
optimal, supporting our observation of the involvement of a MEK-independent pathway in insulin
activated cell proliferation.
Role of ERK ill the MBA-15.4 osteoblast response to insulin
Insulin markedly increased proliferation in MBA-15.4 osteoblasts in a MEK-and PI3-kinase-
independent manner. We therefore wondered whether insulin could activate ERK in bone cells. In
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many cell types previously studied, insulin treatment induces the activation of ERK (Lazar et aI,
1995). Likewise, in osteoblasts, insulin stimulated ERK-l/2 activity, but this activation was weak and
transient. Compared to insulin, TPA and FCS strongly stimulated ERK activity, and ERK
phosphorylation was still detectable 24 h after treatment. This suggested that in comparison to known
mitogens, ERK activation may not be so important in insulin-induced proliferation of MBA-15.4
osteoblasts.
Wortmann in, the PB-kinase inhibitor, had no effect on either insulin or 20% FCS-induced DNA
synthesis. Therefore, to exclude the possibility that the inhibitor was not working optimally, activation
of AktlPKB, a well-established downstream target of PB-kinase, was investigated (Burgering and
Coffer, 1995). Insulin treatment caused a prolonged increase in AktIPKB phosphorylation.
Pretreatment with the PB-kinase inhibitor completely blocked insulin signaling to AktlPKB. This
indicates that insulin mediates the activation of a wortmannin-sensitive PB-kinase upstream of
AktlPKB, which is not involved in proliferation ofMBA-15.4 osteoblasts.
Insulin can signal through two major pathways, both of which may involve ERK as a downstream
substrate. Next, we used the inhibitors to further investigate the role that ERK plays in bone cells.
Using UO126, the MEK-l and -2 inhibitor, we found immediate inhibition of insulin- and FCS-
stimulated ERK activity, and this inhibition lasted for 24 h, in agreement with a negative effect on cell
cycle. Also, the PB-kinase inhibitor, wortmann in, decreased insulin-induced ERK activity at all time
points but only visibly affected 20% FCS-induced ERK activation after 24 h. In the MBA-15.4
preosteoblast cell line, both insulin and FCS activation ofERK was MEK-dependent. Further, whereas
insulin stimulation of ERK was also Plê-kinase-dependent, FCS stimulation seemed to only slightly
involve PB-kinase, since wortmannin only visibly inhibited ERK after 24 h. Therefore insulin
signaling to ERK was dependent on both MEK and PB-kinase, but this had no effect on cell
proliferation. In contrast, both ERK activation and proliferation induced by 20% FCS was almost
entirely dependent on MEK-ERK (Fig.13).
Comparison with II more mature cell line, MBA-15.6
In the immature MBA-15.4 mouse cell line, the MEK-ERK and PB-kinase signaling pathways
appeared not to be essential for insulin's effect on DNA synthesis. We repeated the experiment with
increasing UO126 concentrations in the more mature mouse cell line, MBA-I5.6. Again 20% FCS-
induced proliferation was abolished by the inhibitor, whereas insulin was resistant to all concentrations
of the inhibitor. It therefore seems that in both an immature and more mature mouse cell line the
classical signaling pathways are not involved in insulin- stimulated proliferation.
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Figure 13: The signal transduction cascade stimulated by growth factors such as
20% FCS in MBA-15.4 osteoblasts. The MEK inhibitor, U0126 blocked proliferation.
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Figure 14: The classical insulin signal transduction pathways (in black). Active ERK can
hyperphosphorylate Sos, causing dissociation ofGrb2-Sos complexes (in red). The negative feedback
terminates the insulin signal and deactivates Ras. MEK inhibition blocks the negative signal from
ERK, resulting in a prolonged Ras activation (Modified from Goalstone and Draznin, 1998).
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Comparison with a humall immature osteoblast cell line, MG-63
The MG-63-human osteoblast cell line, like the MBA-15.4, is considered to be a less differentiated or
immature cell line. Both insulin and TPA, which was included for comparison, stimulated
proliferation. However, in contrast to the mouse cell line, the human cells responded to MEK
inhibition with a marked decrease in proliferation. While this finding may be simply due to differences
between immortal cell lines or a drug effect of U0126, it also may indicate species differences, with
the mouse cells being independent and the human cells being dependent on MEK for DNA synthesis.
Wortmann in, the PB-kinase inhibitor, partially blocked both TPA- and insulin- induced proliferation.
However, MEK inhibition completely blocked TPA and partially prevented insulin stimulated cell
proliferation. With TPA treatment, blocking both pathways at the same time decreased proliferation to
the same extent as MEK inhibition alone. Phorbol esters like TPA can mediate their effects through
the direct activation of PKC-Raf-MEK-ERK, bypassing receptor signaling (Fig.15). However, TPA
stimulates PB-kinase in a number of cell types, including 3T3-L I adipocytes (Nave et al, 1996) and
JB6 cells (Huang et al, 1998). This is probably due to transactivation of receptors by TPA. Recently, it
has been shown that TPA cannot activate ERK or cell cycle in the absence of EGF receptor (Chen et
al, 2001). InMG-63 osteoblasts, it seems that although both MEK and PB-kinase are involved in TPA
signaling to proliferation, the MEK-ERK limb of the pathway is dominant. Therefore although some
of the signal goes through PB-kinase, all of the signal eventually goes through ERK (Fig.l5). This
cross-talk of PB-kinase with Ras-Raf-MEK has been reported for many cell lines, including 3T3-Ll
adipocytes (Suga et al, 1997), L6 rat skeletal muscle (Cross et al, 1994) and COS cells (Wennstrom
and Downward, 1999). In contrast, whereas the two inhibitors on their own both partially inhibited
insulin-stimulated proliferation, combining the two completely blocked DNA synthesis, as reported
for the human neuroblastoma cell line, SH-SY5Y (Kurihara et aI, 2000). This indicated that in the
human cell line, insulin signals via two separate pathways, one going through MEK-ERK and one
dependent on PI3-kinase and inhibition of both totally accounts for the increase in proliferation
(Fig.16).
Looking at Fig 6C and Fig 7A and B, there is evidence in all three experiments of a possible drug
effect ofU0126, because of the severe inhibition of basal (0.5% FCS) DNA synthesis. UOl26 had a
much greater inhibitory effect on TPA induced-proliferation than on insulin-induced proliferation,
which could be explained by a partial decrease by drug effect, seen in 0.5% FCS controls, insulin and
TPA- treated samples, but with an additional true inhibition of MEK-ERK in the TPA samples.
However, the relative decrease in the basal DNA synthesis under conditions of 0.5% FCS culture is
-85%, statistically no different from the -85% relative decrease in proliferation seen with TPA (one-
way ANOV A with Bonferroni Posthoc, results not shown). The relative decrease produced by U0126
on insulin signalling was only -50%, which was statistically less than the change produced in the other
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Figure 15: The signal transduction pathways stimulated by the phorbol ester, TPA, in a human
osteoblast cell line, MG-63. TPA activates PKC independently of receptor activation. A recent
report indicates that TPA activation ofERK requires EGF receptor activation, suggesting possible
transactivation of the receptor via TPA. This can lead to PB-K activation. Blocking PB-kinase
partially prevented DNA synthesis, whereas MEK inhibition completely blocked proliferation.
This indicates that some of the TPA signal goes though PI3-K, which feeds onto MEK-ERK.
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Figure 16: The signal transduction pathway stimulated by insulin in a human osteoblast
cell line, MG-63. Insulin signals through PI3-kinase and MEK-ERK and inhibition of
both pathways completely abolished proliferation.
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2 treatment groups. A true drug effect should have affected all 3 to the same extent, with additional
inhibitory effects seen on TPA only. We therefore interpret the data as indicating a very strong
dependence on MEK of basal proliferation and that induced by TPA, whereas insulin signalling is only
partially MEK dependent. This needs to be further investigated to conclusively rule drug effect out or
tn.
Effects of GCs and PTP inhibition on insulin-induced proliferation in immature mouse osteoblasts,
MBA-15.4
Clinically, long-term high dose steroid use is the most common cause of secondary osteoporosis. Our
group have shown that in vitro GCs impair osteoblast proliferation of an immature cell line, MBA-
15.4, which correlated with a decreased response to growth factors and a blunted ERK-l/2 activation
(Hulley et aI, 1998). Sodium orthovanadate repaired GC-impaired ERK activation and cell
proliferation by inhibiting protein tyrosine phosphatases thus prolonging the activation of the kinase
cascade. This was confirmed in a rat model of steroid-induced osteoporosis, where daily vanadate
supplementation improved bone strength and bone formation, thus providing protection against the
negative effects of GC treatment (Hulley et al, 2001). Vanadate may act by blocking GC-induced
upregulation of PTPs or preventing inhibition of tyrosine phosphorylated substrates, desensitizing the
pathway to mitogenic stimulation. Moreover, the ability of vanadium to act as a insulin mimetic makes
it useful as treatment of diabetes in humans (Cohen et aI, 1995; Goldfine et al, 1995) and animals
(Meyerovitch et aI, 1987; Briehard et al, 1988). Inhibition of PTPs and increased insulin receptor
phosphorylation are postulated to be the mechanism of action whereby vanadium exert its insulin-
enhancing effect. Candidate phosphatases that negatively regulate this pathway include PTP-IB
(Goldstein et al, 2000) and SHP-l (Bousquet et al, 1998). PTP-lB knockout mice are resistant to
obesity when fed a high-fat diet and showed increased insulin sensitivity (Elchebly et aI, 1999).
Overexpression of PTP-IB in adipocytes suppress PI 3-kinase activation (Venable et al, 2000). This
dampening of important regulatory signals stresses the role that phosphatases can play in human
disease.
Candidate phosphatases that have been reported to negatively affect growth factor and insulin
signaling pathways, include SHP-I and PTP-IB. With co-immunoprecipitation, we were able to
demonstrate association between molecules in the Raf-MEK-ERK cascade and tyrosine phosphatases.
We successfully demonstrated that ERK and MEK co-immunoprecipitate with PTP-IB. However,
although we were unable to demonstrate this for Raf, Raf was detectable in these cells. Co-
immunoprecipitation of MEK with PTP-I B, which is serine and not tyrosine phosphorylated, and
ERK with Raf, which is not directly upstream of ERK, indicated that a multiprotein complex is pulled
down. Likewise, SHP-I co-immunoprecipitated with ERK, MEK and also Rafrespectively. We could
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therefore say that PTP-1 Band SHP-1 are present in our cells and associate with molecules in the
mitogenic kinase cascade, and therefore may be vanadate targets. We further confirmed that SHP-1 is
associated with active, tyrosine-phosphorylated ERK. This may indicate that SHP-I associates with
active tyrosine-phosphorylated ERK in order to dephosphorylate it. However, more direct evidence of
this is needed before such a conclusion can be made.
The next question that I wanted to answer is whether GC treatment inhibits insulin-induced osteoblast
proliferation in the same way as it inhibits growth factor induced proliferation. Pretreatment with
different concentrations of the GC dexamethasone dose-dependently decreased insulin-induced
proliferation in the MBA-15.4 preosteoblasts. Likewise, in the human MG-63 preosteoblasts, Dex
inhibited proliferation of cells growing in 10% FCS. The PTP inhibitor, sodium orthavanadate
completely reversed GC-impaired proliferation of the MG-63s. Also, we know that vanadate corrects
the decrease in TPA-induced proliferation caused by GC treatment (Hulley et al, 1998). We were able
to demonstrate in both a mouse and human immature osteoblast cell line that vanadate can oppose the
negative effects that steroids have on TPA and 10% FCS treatment.
Since Dex inhibited insulin-induced proliferation, we were interested to see whether vanadate would
protect against steroid-impaired proliferation. It is not possible to maintain live cultures in the
complete absence of FCS and since FCS is a cocktail of GFs, we lowered the serum concentration to
prevent our insulin responses from being masked by high GF levels. We initially serum starved in 1%
FCS before changing the experimental conditions to serum starving in 0.5% FCS, because this gave a
more reproducible insulin stimulation. Prolonging the time of exposure to Dex from 48 h to 72 h, and
treating concurrently with insulin and vanadate for the last 24 h, resulted in a marked decrease in
proliferation, but with no visible salvage by sodium orthovandate. Next we prolonged the vanadate
treatment from once for 24 h to twice over a period of 48 h. However the vanadate was still unable to
correct the steroid-impaired proliferation, and since vanadate functions by inhibition of PTPs this
indicated that vanadate-sensitive phosphatases may not be involved. We therefore concluded that
TPA- and growth factor- induced ERK activation and cell proliferation is markedly impaired by GCs,
while co-treatment with vanadate provides protection by reversing the effects of GCs. However this is
not true for insulin signaling in osteoblasts which were growth-impaired by steroids, but fairly
resistant to the effects of vanadate. GCs decrease the response to growth factors such as TPA and 10%
FCS of the mitogenic signaling cascade, causing a blunted Raf-MEK-ERK activation and this was
repaired by co-treatment with the PTP inhibitor, vanadate (Hulley et al, 1998). In contrast, vanadate
had no effect on GC-impaired insulin signaling. Although we showed that the PTPs, PTP-IB and
SHP-1, associates with Raf, MEK and ERK, this is unlikely to be important for insulin signaling, since
insulin does not use the Raf-MEK-ERK pathway for proliferation in MBA-l5.4 and 15.6 mouse
osteoblasts.
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Figure 17: Possible alternative signaling pathways in MBA-15.4 osteoblasts.
Ras-dependent pathways include the downstream effectors RalGEF, the recently
discovered PLCepsilon and the SAPK, JNK. The Jak/Stat pathway is activated
independent ofRas and active Stat translocates to the nucleus.
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Alternative pathways
Insulin activated ERK activity in a mouse preosteoblast cell line was sensitive to both MEK and PI3-
kinase inhibition. However, proliferation in response to insulin was independent of MEK and PI3-
kinase in both young and mature mouse osteoblasts. In contrast, insulin- induced cell proliferation in a
human cell line was dependent on both MEK and PB-kinase. It seems that in MBA-15.4 and MG-63
cell lines, insulin-induced osteoblast proliferation is signaled through different pathways. Since both
the MBA-15.4 and 15.6 cell lines used a MEK and PI3-kinase-independent pathway in response to
insulin this may indicate a species difference. However, this would have to be confirmed by
experiments in primary culture of mouse and human osteoblasts. Also the unique finding that, in
mouse cells activation, of both MEK and PB-kinase is not required for proliferation indicated that a
different or even completely novel pathway may be involved in insulin induced-proliferation in mouse
bone cells.
Ras-Ral
Ras signals to the cell cycle through Raf and PI3-kinase, but a third effector pathway is also frequently
involved (Fig.17). Ral guanine nucleotide exchange factors (GEFs) are classified as the third class of
Ras effectors that is functional in vivo. In AI4-NU:I3T3 cells, insulin induced activation of Ral is
blocked by a dominant negative Ras, providing evidence that the RaIGEF-Ral pathway is downstream
of Ras and involve in insulin signaling (Wolthuis et al, 1998). RalGEFs activate Ral, a Ras-like small
GTPase, by catalyzing the exchange of GOP for GTP. The Ral isoforms RalA and RalB are 85%
identical and 50% identical to Ras. The four known GEFs for Ral includes RaiGOS, RgI, RIf and Rgr
(Wolthuis and Bos, 1999). The RalGDS-related protein Rgr forms part of the fusion protein Rsc
(D'Adamo et aI, 1997). The RalGEF contains a carboxy-terminal Ras binding domain for binding to
active or GTP-bound Ras. An increase in intracellular calcium levels can cause activation of the
RalGEFs independent of Ras-binding (Hofer et al, 1998). Ral is present in cytoplasmic vesicles and at
the plasma membrane. Activation of RalGEFs involves binding of Ras and induction of a
conformational change of the RBD and recruitment to Ral at the plasma membrane. Proteins that have
been identified as possible Ral downstream effectors, include phospholipase Dl (PLD1) (Jiang et al,
1995), _Ral-_Qindingprotein I (RalBPl) (Cantor et al, 1995) and filamin (Ohta et al, 1999). Other Ral-
interacting proteins include NF-KB which regulates cyclin Dl transcription and activation, and Ral-
mediated phosphorylation of the transcription factors c-Jun and AFX (Henry et ai, 2000). In addition,
insulin-induced c-Jun phosphorylation requires Ras, Ral and c-jun NH2 terminal kinase (INK)
activation, a still elusive JNKK and possibly Src (De Ruiter et ai, 2000). Using sulfasalazine, a NF-KB
inhibitor, we were unable to show inhibition of insulin-induced proliferation with various
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concentrations of the inhibitor, indicating that NF-KB may not be involved as an alternative pathway
in the MBA-15.4 preosteoblasts (results not shown). Preston et aI., (1997) similarly found that
sulfasalazine had no inhibitory effect on the more mature UMR-I06 rat cells after 24 or 48 h
proliferation at any non-toxic concentration. Identification of the Ral downstream targets are important
for understanding this pathway labeled as the third Ras effector that has been implicated in insulin
signaling.
Ras-Pl.Cepsilon
Another pathway that may be involve is the recently identified and novel fourth class of mammalian
phosphoinositide-specific phospholipases, phospholipase C epsilon (PLCE) (Kelley et aI, 2001).
PLCepsilon contains an amino-terminal RasGTP exchange factor domain and two carboxy-terminal
Ras-association domains, RAl and RA2. PLCepsilon can bind to activated Ras via its RA2 domain,
while RAl binds to inactive Ras with low affinity (Cullen, 2001). However, the mechanism of
PLCepsilon activation by Ras is still unclear and may involve translocation to the plasma membrane
and activation via the RA 1 and RA2 tandem domains (Fig.17).
Ras-JNK
Apart from ERK activation, Ras can also activate the stress-activated protein kinases (SAPK), JNK
and p-38. Activation of JNK by insulin has been demonstrated in studies overexpressing human
insulin receptors. In Rat 1 fibroblasts insulin-stimulated JNK activity and insulin-induced AP-I
transcriptional activity were found to be Ras-dependent (Miller et aI, 1996). In Chinese hamster ovary
cells (CHO) acute insulin treatment induced a time-dependent increase in both in JNK and ERK
activity. However, prolonged insulin exposure markedly inhibited INK activity while inducing
sustained ERK activation (Desbois-Mouthon et aI, 1998). This study indicated that insulin
differentially regulates JNK and ERK and provided evidence that insulin exerts opposite effects on
JNK activity according to the duration of treatment (Fig.17).
Ras-independent signaling via JAK-STATS
The Janus kinase (Jak) and signal-transducer and activator of transcription (Stat) are necessary
components of cytokine receptor signaling. Receptor bound Stat are phosphorylated by Jaks,
dissociate from the receptor, dimerize and translocate to the nucleus (Fig.17). Chen et aI., (1997) show
that Stat5B is a direct substrate of the insulin receptor without the involvement of Jak. Insulin induces
tyrosine phsophorylation of Stat5B, which leads to its activation and translocation to the nucleus.
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Insulin can also activate Stat3, independently of Ras-ERK and PB-kinase signal transduction (Coffer
et aI, 1997). Also suppressor of cytokine signaling (SOCS) -3, a negative regulator restricted to
activators of the cytokine receptor family, has been shown to be expressed by interaction with the
insulin receptor in 3T3-Ll adipocytes (Emaneulli et aI, 2000). Once induced, SOCS-3 inhibits insulin
activation of Stat5B without modifying the insulin receptor tyrosine kinase activity. Firstly, from these
studies it seems that insulin can induce gene transcription by a signaling cascade distinct from the
classical ERK and PB-kinase pathways. Secondly, a direct signaling path may exist involving only the
insulin receptor, Stat5B or Stat3 and the nucleus. However, tyrosine phosphorylation of the Jak
proteins induced by insulin has been illustrated indicating possible involvement of Jak proteins
upstream of Stats in insulin signal transduction (Giorgetti-Peraldi et al, 1995; Saad et al, 1996).
Furthermore, SOCS-l negatively regulates insulin signaling through suppression of IRS-I
phosphorylation and inhibition of Jak activation (Kawazoe et al, 2001).
In conclusion, we were able to show that insulin does playa role as an osteoblast mitogen. Three
immature bone cell lines responded with a marked increase in osteoblast proliferation, compared to a
much weaker response by the differentiated UMR-I06 rat cell line. In the immature mouse MBAI5.4,
20% FCS-induced DNA synthesis was completely dependent on the mitogenic Raf-MEK-ERK
signaling pathway, whereas insulin did not rely on PI3-kinase or the Raf-MEK-ERK kinase cascade to
signal proliferation. In an immature human cell line MG-63, the phorbol ester TPA only partially
depended on PI3-kinase, and it seems as if MEK-ERK was the dominant pathway used for
proliferation. Also, in contrast to the MBA-15.4 osteoblasts, the MG-63s equally depended on PI3-
kinase and the Raf-MEK-ERK cascade for DNA synthesis in response to insulin. There are clear
differences in the proliferative potential of bone cells in response to insulin, which may be due to
differences between immortal cell lines, or even the stage of differentiation of the cells. As with the
mitogens, TPA and 20% FCS, steroid treatment negatively affected insulin-stimulated proliferation.
The PTP inhibitor, vanadate protects against GC-induced decreases in proliferative response to TPA
and FCS. However, vanadate failed to reverse steroid-impaired proliferation in response to insulin.
Although we showed association of candidate phosphatases, PTP-IB and SHP-l, with molecules in
the kinase cascade, it seems as if they are not important as negative regulators in the insulin signaling
pathways in MBA-15.4 mouse osteoblasts. The novel proliferative pathway by which insulin signals
in MBA-15.4 and 15.6 osteoblasts remains to be discovered.
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